Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU744002B2 - Benzamine derivatives - Google Patents
[go: Go Back, main page]

AU744002B2 - Benzamine derivatives - Google Patents

Benzamine derivatives Download PDF

Info

Publication number
AU744002B2
AU744002B2 AU19647/99A AU1964799A AU744002B2 AU 744002 B2 AU744002 B2 AU 744002B2 AU 19647/99 A AU19647/99 A AU 19647/99A AU 1964799 A AU1964799 A AU 1964799A AU 744002 B2 AU744002 B2 AU 744002B2
Authority
AU
Australia
Prior art keywords
methyl
formula
oxadiazol
phenyl
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19647/99A
Other versions
AU1964799A (en
Inventor
Soheila Anzali
Sabine Bernotat-Danielowski
Hans-Peter Buchstaller
Dieter Dorsch
Joachim Gante
Horst Juraszyk
Werner Mederski
Guido Melzer
Hanns Wurziger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU1964799A publication Critical patent/AU1964799A/en
Application granted granted Critical
Publication of AU744002B2 publication Critical patent/AU744002B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Description

WO 99/31092 WO 9931092PCT/EP98/07 673 BENZAMIDINE DERIVATIVES AS COAGULATION FACTOR XA INH I BITOR The invention relates to compounds of the formula I in which R is -C(=NH)-NH 2 which can also be monosubstituted by -COA, -COilC(R 5 2 -COQA, -OH or by a conventional amino-protective group, N
HN-(
CH 3 R 2 i s H, A, OR 5, N (R 5 2
NO
2 CN, Hal, NR 5 COA, NHCOAr,
NHSO
2 A, NHS0 2 Ar, COOR, CON 2 CONHAr, COR, COAr, S A or S Ar, R is R 5 or C (R 5 2 ]mCOOR R 3 and X together are also thus forming a membered ring, where R 3 is -C=O and X is N, R4 is A, cycloalkyl,
-CR
5
=CR
5 -Ar, R 5 is H, A or benzyl, X is 0, NR 5 or CH 2
-[C(R
5 2 ]mAr, -[C(R 5 2 ]mHet or 2- Y is 0, NRs, N(C N(C (R 5 2 1 Het, -N N- N[(C (R 5 2
]._COOR
5 RS RS N \N
N
N[C (Rs) 2] ,CON (Rs) 2 N [C (Rs) 2]-CONRsAr or N [C (Rs) 2]1 CONAr 2 W is a bond, -SO 2 Ca- or -CONR 5 A is alkyl having 1-20 C atoms in which one- or two CH, groups can be replaced by 0 or S atoms or by 5
=CR
5 groups and/or 1-7 H atoms can be replaced 'by F, -Ar is naphthyl or phenyl which is unsubstituted or mono-, di- or trisubstituted by R1, A, Ar', OR 5 N (R 5 2
NO
2 CN, Hal, NHCOA, NHCOAr', NHSO 2
A,
NHSO
2
COOR
5
CON(R
5 2 CONHAr', CaR 5 COAr', S(O),A or S(0) EAr, Ar' is naphthyl or phenyl which is unsubstituted or mono-, di- or trisubstituted by R1, A, OR', N(R 5 2 1
NO
2 CN, Hal, NHCOA., COOR', CON(Rs) 2
COR
5 or *Het is a mono- or bicyclic saturated or unsaturated heterocyclic ring system which contains one, two, three or four identical or different hetero atoms such as nitrogen, oxyrgen and sulfur and which is unsubstituted or mono- or polysubstituted by Hal, A, Ar'I, OR 5 ,I COOR', CN, N (R s) 2 N0 2 1 -NHCOA, NHCOAr' and/or carbonyl oxygen, Hal is F, Cl, Br or I, P\kWPDOCS\CASPECI7483620.d--30/1 1/01 m is 0, 1, 2, 3 or 4, n isO0, 1or 2, and salts thereof, with the proviso that the following compounds are excluded: 1 -isopropylamino-3-[4-(5-methyl-[ 1,2,4]oxadiazol-3-yi)-phenoxy]-propan-2-o; 1 -[2-(3,4-dimethoxy-phenyl)-ethylamilo-3-[4-(5-methyl-[1 ,2,4]oxad iazol-3-yI)-phenoxy]propan-2-oI; and (2-m eth oxy-p hen yl)-p iperazi n -1 -yI]-3-[4-(5-mnethyl-[1, 2,4]oxad i azol-3-yI) -ph en oxy]- P:\WPDOCS\CAB\SPECI7483620.doc-30/I 1/01 -3a- The invention also provides the optically active forms, the racemates, the diastereomers and the hydrates and solvates of these compounds.
The invention was based on the object of discovering novel compounds having valuable properties, in particular those which can be used for preparing medicaments.
It has been found that the compounds of the formula I 0 and their salts have very useful pharmacological properties, coupled with good tolerability. In particular, they have factor Xa-inhibiting properties and can therefore be employed for combating and preventing thromboembolic disorders such as thrombosis, .myocardial infarction, arteriosclerosis, inflammations, 15 apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens.
Aromatic amidine derivatives having antithrombotic action are known, for example, from EP 0 540 051 B1.
Cyclic guanidines for the treatment of thromboembolic disorders are described, for example, in WO 97/08165.
Aromatic heterocycles having factor Xa-inhibiting activity are known, for example, from WO 96/10022.
The antithrombotic and anticoagulant effect of the 2 compounds according to the invention is attributed to the inhibiting action on the activated coagulation protease, known under the name factor Xa, or to the inhibition of other activated serine proteases such as factor VIIa, factor IXa or thrombin.
4 inhibition of other activated serine proteases such as factor VIIa, factor IXa or thrombin.
Factor Xa is one of the proteases which is involved in the complex process of blood coagulation. Factor Xa catalyses the conversion of prothrombin into thrombin.
Thrombin cleaves fibrinogen into fibrin monomers which, after crosslinking, contribute fundamentally to thrombus formation. An activation of thrombin can result in the occurrence of thromboembolic disorders.
An inhibition of thrombin, however, can inhibit the fibrin formation involved in the formation of a thrombus.
The inhibition of thrombin can be measured, for example, by the method of G. F. Cousins et al. in Circulation 1996, 94, 1705-1712.
Inhibition of factor Xa can thus prevent thrombin formation.
The compounds of the formula I according to the invention and their salts intervene in the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.
The compounds of the formula I according to the invention can furthermore function as inhibitors of the blood clotting factors factor VIIa, factor IXa and thrombin of the blood clotting cascade.
The inhibition of factor Xa by the compounds according to the invention and the measurement of the anticoagulating and antithrombotic activity can be determined by customary in vitro or in vivo methods. A suitable method is described, for example, by J. Hauptmann et al. in Thrombosis and Haemostasis 63, 220-223 (1990).
The inhibition of factor Xa can also be measured, for example, by the method of T. Hara et al. in Thromb.
S Haemostas. 71, 314-319 (19941.
5 The blood clotting factor VIIa initiates, after binding to tissue factor, the extrinsic part of the blood clotting cascade and contributes to the activation of factor X to factor Xa. An inhibition of factor VIIa thus prevents the formation of factor Xa and thus a subsequent formation of thrombin.
The inhibition of factor VIIa by the compounds according to the invention and the determination of the anticoagulant and antithrombotic activity can be determined using customary in vitro or in vivo methods.
A customary process for measuring the inhibition of factor VIIa is described, for example, by H. F. Ronning et al. in Thrombosis Research 1996, 84, 73-81.
The compounds of the formula I can be employed as medicaments in human and veterinary medicine, in particular for combating and preventing thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammations, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens.
The invention provides the compounds of the formula I and their salts, and also a process for preparing compounds of the formula I according to Claim 1 and their salts, characterized in that a) they are liberated from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent, by i) liberating an amidino group from its oxadiazole derivative by hydrogenolysis, ii) replacing a conventional amino-protective group by treatment with a solvolysing or hydrogenolysing agent with hydrogen or 6liberating an amino group which is protected by a conventional protective group, or b) that for preparing compounds of the formula I in which R 1 is
N
O N
O
HN or N O CH 3
R
3 and X together are thus forming a membered ring, Y is NR 5 -N N- N N or
R
5
R
NN
W is -SO 2 or -CO-, and R 2 and R 4 are as defined in Claim 1, a compound of the formula II
R
1
R
2
O
S. R 3
R
in which 7-
N
O N"
O
R
1 is HN or N O CH,
R
3 and X together are thus forming a membered ring, Y is NR s -N N- N or
R
5
R
NN
and R 2 and R 5 are as defined in Claim 1, is reacted with a compound of the formula III
R
4 -W-L III in which W is -S02- or -CO-,
R
4 is as defined in Claim 1, and L is Cl, Br, I or a free or a reactive functionally derivatized OH group, or c) that for preparing compounds of the formula I 8 N-o in which R 1 is H 4 or N- 0 CH 3
R
3 and X together are thus forming a membered ring, Y is O, W is a bond, and R 2 and R 4 are as defined in Claim 1, a compound of the formula II
R.
R2 R3 in which R1 is HN or N- O CH 3
R
3 and X together are thus forming a membered ring, Y is O, and R 2 is as defined in Claim 1, is reacted with a compound of the formula IV
R
4 -W-OH
IV
in which 9- W is a bond, and R 4 is as defined in Claim 1, or d) that for preparing compounds of the formula I No y '.o in which R 1 is 1 or N 0 CH 3
R
3 and X together are thus forming a membered ring, Y is -N N-, k__I W is a bond,
R
4 is -[C(R 5 2 ]mAr or -[C(RS) 2 ]mHet, m is 0, and R 2 is as defined in Claim 1, a compound of the formula V in which 10
N
O
O
RI is HN- or N= 0 CH 3
R
3 and X together are thus forming a membered ring, and L is Cl, Br, I or a free or a reactive functionally derivatized OH group, and R 2 is as defined in Claim 1, is reacted with a compound of the formula VI
R
4 -W-Y-H VI in which W is a bond, Y is -N N-
R
4 is [C(R 5 )2mAr or [C(R 5 2 mHet and m is 0, or e) that for preparing compounds of the formula I N
N
O
in which R is H or N n O CH 3 11
R
3 and X together are thus forming a membered ring, Y is NR 5 -N N- -N N or
R
5 N N W is -CONH-, and R 2 and R 4 are as defined in Claim 1, a compound of the formula II
R
1 3H
R
2 in which
N
O O R is HN- or N= O
CH
3
R
3 and X together are thus forming a membered ring, Y is NR 5 -N N- -N or -N j N S 12
R
5
R
NN
and R 2 and R 5 are as as defined in Claim 1, is reacted with a compound of the formula VII
R
4 -N=C=O VII in which
R
4 is as defined in Claim 1, or f) that for preparing compounds of the formula I
N
0
N
0 in which R 1 is HN or N= O CH 3
R
3 and X together are thus forming a membered ring, Y is N[C(R 5 2 ]m-COOR, W is SO 2 and R 2 and R 4 are as defined in Claim 1, a compound of the formula II 13
R
1
R
3 in which
N-
0
{-N
R is HN or N O
CH,
R
3 and X together are thus forming a membered ring, Y is N[C(Rs) 2 ]m-COOR, and R 2 and R 5 are as defined in Claim 1, is reacted with a compound of the formula VIII
R
4
-SO
2 -L VIII in which L is Cl, Br, I or a free or a reactive functionally derivatized OH group, and R 4 is as defined in Claim 1, or g) that for preparing compounds of the formula I in which X is NH and 14
R
3 is H and R 1
R
2
R
4 Y and W are as defined in Claim 1, these compounds are liberated from their oxazolidinone derivatives by treatment with a solvolysing or hydrogenolysing agent, or h) that for preparing compounds of the formula I in which R 1 is -C(=NH)-NH 2 a cyano group is converted into an amidino group, or i) in a compound of the formula I, one or more radicals Y, R 1
R
2
R
3 and/or R 4 are converted into one or more radicals R 1
R
2
R
3 and/or R 4 by, for example, i) hydrolysing an ester group to give a carboxyl group, ii) reducing a nitro group, iii) acylating an amino group, and/or k) converting a base or acid of the formula I into one of its salts.
For all the radicals which occur several times, such as, for example, R 5 the meanings thereof are independent of one another.
15 Hereinabove and hereinbelow, the radicals or parameters L, W, X, Y, R R 2
R
3
R
4
R
5 m and n have the meanings given for the formulae I to VIII, unless expressly stated otherwise.
Solvates is [sic] addition compounds with, for example, organic inert solvents, such as, for example, with alcohols such as methanol, ethanol or propanol.
In the above formulae, A is alkyl, is linear or branched, and has 1 to 20, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 C atoms. A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 3- or 4-methylpentyl, 2,3- or 3,3-dimethylbutyl, 1or 2-ethylbutyl, 1-ethyl-1-methylpropyl, l-ethyl-2methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, heptyl, octyl, nonyl or decyl.
A is furthermore, for example, trifluoromethyl, pentafluoroethyl, allyl or crotyl.
OR
5 is OH, OA or benzyloxy, with OA preferably being methoxy, ethoxy, propoxy, butyloxy or hexyloxy.
Cycloalkyl is preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Cycloalkyl is, for example, also the radical of a bicyclic terpene, such as, for example, 3-menthyl; particular preference is given to the camphor-10-yl radical.
COR
5 is acyl and is preferably formyl, acetyl, propionyl, furthermore also butyryl, pentanoyl or hexanoyl.
Hal is preferably F, Cl or Br, but also I.
16
R
2 is preferably H, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, nitro, amino, methylamino, dimethylamino, ethylamino, diethylamino, acetamido, sulfonamido, methylsulfonamido, phenylsulfonamido, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, phenylsulfinyl, phenylsulfonyl, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, furthermore also acyl or benzoyl.
R
2 is, in particular, H.
R
3 is preferably A, benzyl, CH 2 COOH or CH 2 COOA, but in particular H.
R
4 is preferably, for example, A, cycloalkyl, Ar, CH 2 Ar,
CH
2
CH
2 Ar, CH 2 Het, CH 2
CH
2 Het or CH=CH-Ar.
R
5 is H, A or benzyl, but in particular H.
X is O, NH, NA or N-benzyl, furthermore also CH 2
R
3 and X together are also thus forming, together with the -CH 2 -CH-O- unit, a five-membered ring.
Y is preferably, for example, 0, NH, N-methyl, N-ethyl, N-Ar, N-CH 2 -Ar, N-Het, N-CH 2 -Het, N-COOA, N-CH 2 -COOA, N-
CH
2 -COOH, N-CH 2 -COObenzyl, -N N R 5
R
-N -D -N I5N
/N
NCH
2
CONH
2
NCH
2 CONHA, NCH 2
CONA
2
NCH
2
CONR
5 Ar or NCH 2 CONAr 2 W is preferably, for example, a bond, -S02- or -CO-, furthermore also -COO- or -CONH-.
Ar is preferably unsubstituted phenyl or naphthyl, furthermore preferably naphthyl or phenyl which is mono-, di- or trisubstituted, for example by A, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, 17 benzyloxy, phenethyloxy, methyithio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, phenylsulfinyl, phenylsulfonyl, nitro, amino, methylamino, ethylamino, dimethylamino, diethylanino, formamido, acetamido, propionylanino, butyrylamino, methylsulfonanido, ethylsulfonanido, propylsulfonamido, butylsulfonamido, phenylsulfonamido, (4-iethyiphenyl) sulfonanido, carboxyinethoxy, carboxyethoxy, methoxycarbonylmethoxy, methoxycarbonyl ethoxy, hydroxyinethoxy, hydroxyethoxy, methoxyethoxy, carboxyl, methoxycarbonyl, ethoxycarbonyl, cyano, phenylaminocarboiyl, acyl or benzoyl, furthermore also biphenyl.
Ar is therefore preferably, for example, in- or ptolyl, in- or p-ethylphenyl, in- or ppropyiphenyl, in- or p-isopropylphenyl, in- or ptert-butyiphenyl, in- or p-hydroxyphenyl, in- or p-nitrophenyl, in- or p-aininophenyl, in- or p-(Nmethyl amino) phenyl, in- or p-acetamidophenyl, inor p-methoxyphenyl, m- or p-ethoxyphenyl, m- or p-carboxyphenyl, in- or p-inethoxycarbonylphenyl, o-, in- or p N-diinethyl amino) phenyl, in- or p-(Nethylainino)pheiyl, in- or p-(N,N-diethylanino)phenyl, m- or p-acetylphenyl, in- or pformyiphenyl, in- or p-fluorophenyl, in- or pbromophenyl, in- or p-chlorophenyl, mn- or prethylsulfonylphenyl, in- or p-(phenylsulfonamido)phenyl, in- or p-(methylsulfonamido)phenyl, in- or p-methylthiophenyl, furthermore preferably 3,4- or difluorophenyl, 3,4- or dichiorophenyl, 3,4- or dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4diinethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4chioro-, 2 -amino- 3-chloro-,-- 2 -aiino-4 -chloro-, 2-aminoor 2-ainino-6-chlorophenyl, 2-nitro-4-N,Ndimethylainino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3-diaininophenyl, 2,4,6- or 18 3,4,5-trichiorophenyl, 2,4,6-trimethoxyphenyl, 2hydroxy-3, 5-dichiorophenyl, p-iodophenyl, 3,6-dichioro- 4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4bromophenyl, 2,5-difluoro-4-bromophenyl, 3-bromo-6methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4acetamidophenyl, 3-f luoro-4-methoxyphenyl, 3-amino-6methyiphenyl, 3-chloro-4-acetamidophenyl or dimethyl-4-chiorophenyl.
Ar is very particularly preferably phenyl which is unsubstituted or mono-, di- or trisubstituted by amino, OR Hal, CN, alkyl having 1-10 carbon atoms, CF 3
CH
3
SO
2 OCF3, acetamido, -C(=NH)-NH 2 methoxycarbonyl or ethoxycarbonyl, furthermore naphthyl which is monosubstituted by Hal, dimethylamino or alkoxy having 1-6 carbon atoms and also unsubstituted biphenyl.
Ar' is in particular, for example, phenyl or naphthyl, furthermore preferably, for example, m- or p-tolyl, m- or p-ethylphenyl, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, m- or p-tert-butylphenyl, m- or p-hydroxyphenyl, m- or p-nitrophenyl, o-, m- or p-aminophenyl, m- or p-(N-methylamino) phenyl, m- or p-acetamidophenyl, m- or p-methoxyphenyl, m- or p-ethoxyphenyl, m- or p-carboxyphenyl, m- or p-methoxycarbonylphenyl, m- or p-(N,Ndimethyl amino) phenyl, m- or p- (N-ethylamino) phenyl, m- or p-(N,N-diethylamino)phenyl, m- or pacetylphenyl, m- or p-formylphenyl, m- or pfluorophenyl, m- or p-bromophenyl, m- or pchlorophenyl or m- or p-methylsulfonylphenyl.
Het is preferably, for example, 2- or 3-furyl, 2- or 3thienyl, 2- or 3-pyrrolyl, 4- or imidazolyl, 4- or 5-pyrazolyl, 4- or oxazolyl, 4- or 5-isoxazolyl, 4- or thiazolyl, 4- or 5-isothiazolyl, 3- or 4pyridyl, 5- or 6-pyrimidinyl, furthermore preferably l,2,3-triazol-l-, or -5-yl, 1,2,4- 19 triazol-1-, or -5-yl, 1- or 5-tetrazolyl, 1,2,3oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or l,3,4-thiadiazol-2- or -5-yl, l,2,4-thiadiazol-3- or l,2,3-thiadiazol-4- or -5-yl, 3- or 4pyridazinyl, pyrazinyl, 6- or 7iridolyl, 4- or 5-isoindolyl, 4- or benzimidazolyl, 6- or 7-benzopyrazolyl, 6- or 7-benzoxazolyl, 6- or 7benzisoxazolyl, 6- or 7-benzothiazolyl, 2-, 6- or 7-benzisothiazolyl, 6- or 7-benz- 2,1,3-oxadiazolyl, 7- or 8quinolyl, 7- or 8-isoquinolyl, 3-, 7- or 8-cinnolinyl, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 6-, 7- or 8-2H-benzo[l,4]oxazinyl, furthermore preferably l,4-benzodioxan-6-yl, 2,1,3benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5yl.
The heterocyclic radicals may also be partially or fully hydrogenated.
Het may also be, for example, 2,3-dihydro-2-, -4or -5-furyl, 2,5-dihydro-2-, or tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, or -5-pyrrolyl, 2,5-dihydro-l-, or 2- or 3-pyrrolidinyl, tetrahydro-l-, or -4-imidazolyl, 2,3-dihydro-l-, or tetrahydro-1-, or -4-pyrazolyl, 1,4dihydro-1-, or -4-pyridyl, 1,2,3,4-tetrahydroor -6-pyridyl, 3- or 4piperidinyl, 3- or 4-morpholinyl, tetrahydro-2-, or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, or hexahydro-l-, or -4-pyridazinyl, hexahydroor -5-pyrimidinyl, 2- or 3piperazinyl, l,2,3,4-tetrahydro-l-, or -8-quinolyl, -1,2,3,4-tetrahydro-l-, or -8-isoquinolyl, 7- or 8-3,4-dihydro-2H-benzo[1,4]oxazinyl, furthermore preferably 2, 3 -methylenedioxyphenyl, 3,4- 20 methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or -6-yl, 2,3-(2-oxomethylenedioxy)phenyl or else 3,4-dihydro-2H-l,5benzodioxepin-6- or -7-yl, furthermore preferably 2,3dihydrobenzofuranyl or 2,3-dihydro-2-oxofuranyl.
Het is unsubstituted or mono- or polysubstituted by Hal, A, Ar', COOR 5 CN, N(R 5 2
NO
2 Ar-CONH-CH 2 "Poly" means di, tri, tetra or penta.
Het is very particularly preferably thiazole-2-, 4- or thiophen-2- or -5-yl, chroman-6-yl, pyridin-2-, or -4-yl, pyrimidin-2- or -5-yl, benzothiophen- 2-yl, 1,3-benzodioxol-4- or -5-yl, 1,4-benzodioxan-5or -6-yl, 2,1,3-benzothiadiazol-4- or -5-yl which is unsubstituted or mono- or polysubstituted by Hal, A, phenyl, OR s
COOR
5 CN, N(R 5 2
NO
2 NHCOA, NHCOphenyl and/or carbonyl oxygen.
The compounds of the formula I may have one or more chiral centres and may therefore be present in various stereoisomeric forms. The formula I embraces all of these forms.
Consequently, the invention provides in particular those compounds of the formula I in which at least one of the abovementioned radicals has one of the preferred meanings given above. Some preferred groups of compounds can be expressed by the following moieties Ia to Ii which correspond to the formula I and where the radicals which are not defined more specifically have the meaning given for the formula I, but where in Ia R 2 is H; in Ib R 3 is R 5 or -(CH 2 )m-COOR 5 in Ic R 4 is A, cycloalkyl, -(CH 2 )nAr [sic],
-(CH
2 )mHet or 7CH=CH-Ar; 21 inId Y is 0, NR', N (CH 2
-COOR
5 N (CH 2 rn-Ar, N (CH 2 ),n-Het, ~NU N/ in Ie A in If Ar is alkyl having 1-20 C atoms in which one or two CH 2 groups may be replaced by -CH=CH- groups and/or 1-7 H atoms may be replaced by F; is naphthyl or phenyl which is unsubstituted or mono-, di- or trisubstituted by R 1 A, phenyl, OR 5
N(R
5 2
NO
2 CN, Hal, NHCOA, NHCOphenyl,
NHSO
2 A, NHS 2 phenyl, COOR 5 CON 2 CONHphenyl, COR 5 COphenyl, S(O),A or S Ar; is phenyl; in Ig Ar' in Ih Het is thiazol-2-, or -5-yl, thiophen-2or -5-yl, chroman-6-yl, pyridin-2-, -3or -4-yl, pyrimidin-2- or benzothiophen-2-yl, 1, 3-benzodioxol-4or -5-yl, l,4-benzodioxan-5- or -6-yl or 2,1,3-benzothiadiazol-4- or -5-yl which is unsubstituted or mono- or polysubstituted by Hal, A, phenyl, OR COOR', CN, N1 R 5 2
NO
2 NHCOA, NHCOphenyl and/or carbonyl oxygen; 22 in Ii R1 is -C -NH 2 which can also be monosubstituted by -COA, -CO- (CH 2 )m-Ar, -COOA or OH, or is N, N
CH
3 R 2 is H,
R
3 is R 5 or (CH 2 )m COOR, R 3 and X together are also thus forming a 5-memrbered ring, R 4 is A, cycloalkyl, -(CH 2 )mAr, -(CH 2 )mHet or -CH=CH-Ar, R 5 is H, A or benzyl, X is 0, NR 5 or CH 2 Y is 0, NR 5
N(CH
2 )m-Ar, N(CH 2 ),-Het,
N(CH
2 )m,,COOR, -N N- N -N- -N N
R
5
R
or N
N
'of
NCH
2
-CONH
2
NCH
2 -CONHA, NCH 2
-CONA
2
NCH
2
CONR
5 A or NCH 2 -CONAr 2 is a bond, -SO 2 -COO- or -CONH-, is alkyl having 1-20 C atoms in which one or two CH 2 groups may be replaced by -CH=CH- groups arid/or 1-7 H atoms may be replaced by F, is phenyl which is unsubstituted or mono-, di- or trisubstituted by NH 2
OR,
Hal, CN, alkyl having 1-10 carbon atoms,
CF
3
CH
3
SO
2
OCF
3 acetamido,
-NH
2 methoxycarbonyl or ethoxycarbonyl, ,I R C~
CR,
23 furthermore naphthyl which is monosubstituted by Hal, dimethylamino or methoxy and also unsubstituted biphenyl.
Het is thiazol-2-, or -5-yl, thiophen-2or -5-yl, chroman-6-yl, pyridin-2-, -3or -4-yl, pyrimidin-2- or benzothiophen-2-yl, 1,3-benzodioxol-4or -5-yl, 1,4-benzodioxan-5- or -6-yl, 2,1,3-benzothiadiazol-4- or -5-yl which is unsubstituted or mono- or polysubstituted by Hal, A, phenyl, OR,
COOR
s CN, N(Rs) 2
NO
2 NHCOA, NHCOphenyl and/or carbonyl oxygen.
The compounds of the formula I and also the starting materials for their preparation are otherwise prepared by methods known per se, such as are described in the literature (for example in the standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), and in particular under the reaction conditions which are known and suitable for the reactions mentioned. In these reactions, variants which are known per se and are not mentioned here in more detail can also be utilized.
If desired, the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture but are immediately reacted further to give the compounds of the formula I.
Compounds of the formula I can preferably be obtained by liberating the compounds of the formula I from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent.
Preferred starting materials for the solvolysis or S hydrogenolysis are those which otherwise correspond to the formula I but, instead of one or more free amino 24 and/or hydroxyl groups, contain corresponding protected amino and/or hydroxyl groups, preferably those which, instead of an H atom which is bonded to an N atom, carry an amino-protective group, in particular those which, instead of an HN group, carry an R'-N group, in which R' is an amino-protective group, and/or those which, instead of the H atom of a hydroxyl group, carry a hydroxyl-protective group, for example those which correspond to the formula I but, instead of a -COOH group, carry a group -COOR", in which R" is a hydroxylprotective group.
Preferred starting materials also include the oxadiazole derivatives which can be converted into the corresponding amidino compounds.
The introduction of the oxadiazole group is effected, for example, by reacting the cyano compounds with hydroxylamine and reaction with phosgene, dialkyl carbonate, chloroformic ester, N,N'-carbonyldiimidazole or acetic anhydride.
It is also possible for several identical or different protected amino and/or hydroxyl groups to be present in the molecule of the starting material. If the protective groups present differ from one another, in many cases they can be cleaved off selectively.
The term "amino-protective group" is generally known and relates to groups which are suitable for protecting (blocking) an amino group from chemical reactions but which can easily be removed after the desired chemical reaction has been carried out at other sites of the molecule. Typical such groups are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since -the amino-protective groups are removed after the desired reaction (or reaction sequence), their nature and size is otherwise not critical; however, those having 1-20, in particular 1-8 25 C atoms are preferred. The term "acyl group" is to be interpreted in the broadest sense in connection with the present process. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and in particular alkoxycarbonyl, aryloxycarbonyl and, above all, aralkoxycarbonyl groups. Examples of such acyl groups are alkanoyl, such as acetyl, propionyl or butyryl; aralkanoyl, such as phenylacetyl; aroyl, such as benzoyl or toluyl; aryloxyalkanoyl, such as POA; alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl,
BOC
(tert-butyloxycarbonyl), 2-iodoethoxycarbonyl; aralkyloxycarbonyl such as CBZ ("carbobenzoxy"), 4-methoxybenzyloxycarbonyl, FMOC; arylsulfonyl such as Mtr. Preferred amino-protective groups are BOC and Mtr, and furthermore CBZ, Fmoc, benzyl and acetyl.
The term "hydroxyl-protective group" is also generally known and relates to groups which are suitable for protecting a hydroxyl group from chemical reactions but which can easily be removed after the desired chemical reaction has been carried out at other sites of the molecule. Typical such groups are the abovementioned unsubstituted or substituted aryl, aralkyl or acyl groups, and furthermore also alkyl groups. The nature and the size of the hydroxyl-protective groups is not critical, since they are removed again after the desired chemical reaction or reaction sequence; groups having 1-20, in particular 1-10 C atoms are preferred.
Examples of hydroxyl-protective groups are, inter alia, benzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, benzyl and tert-butyl being particularly preferred.
The liberation of the compounds of the formula I from their functional derivatives is effected depending on the protective group used for example with strong 4 acids, expediently with TFA or perchloric acid, but ff^ OC 26 also with other strong inorganic acids, such as hydrochloric acid or sulfuric acid, strong organic carboxylic acids, such as trichloroacetic acid, or sulfonic acids, such as benzene- or p-toluenesulfonic acid. The presence of an additional inert solvent is possible but not always necessary. Suitable inert solvents are, preferably, organic solvents, for example carboxylic acids, such as acetic acid, ethers, such as tetrahydrofuran or dioxane, amides, such as DMF, halogenated hydrocarbons, such as dichloromethane, or furthermore also alcohols, such as methanol, ethanol or isopropanol, and water. Mixtures of the abovementioned solvents are furthermore possible. TFA is preferably used in excess without addition of a further solvent, and perchloric acid is used in the form of a mixture of acetic acid and 70% perchloric acid in a ratio of 9:1.
The reaction temperatures for the cleavage are expediently between about 0 and about 500, and the reaction is preferably carried out at between 15 and 300 (room temperature).
The groups BOC, OBut and Mtr can preferably be cleaved off, for example, with TFA in dichloromethane or with about 3 to 5N HC1 in dioxane at 15-300, and the FMOC group can be cleaved off with an approximately 5 to solution of dimethylamine, diethylamine or piperidine in DMF at 15-300.
Protective groups which can be removed by hydrogenolysis (for example CBZ, benzyl or the liberation of the amidino group from its oxadiazole derivative) can be cleaved off, for example, by treatment with hydrogen in the presence of a catalyst (for example a noble metal catalyst, such as palladium, expediently on a support, such as carbon). Suitable solvents for this reaction are those mentioned above, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF. The hydrogenolysis is generally carried out attemperatures between about 27 0 and 1000 under pressures between about 1 and 200 bar, preferably at 20-300 and 1-10 bar. Hydrogenolysis of the CBZ group is effected readily, for example, on Pd/C in methanol or with ammonium formate (instead of hydrogen) on Pd/C in methanol/DMF at 20-300.
Compounds of the formula I o o in which R is or HN4 N= 0 CH,
R
3 and X together are thus forming a ring, Y is NR 5 -N N- -N N or
R
5
R
N
W is -SO 2 or -CO-, and R 2 and R 4 are as defined in Claim 1, can preferably be obtained by reacting compounds of the formula II with compounds of the formula III.
In the compounds of the formula III, L is preferably Cl, Br, I or a reactively modified OH group, such as, for example, an activated ester, an imidazolide or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy), or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).
28 The reaction is generally carried out in an inert solvent, in the presence of an acid binder, preferably an alkali metal hydroxide, carbonate or bicarbonate or an alkaline earth metal hydroxide, carbonate or bicarbonate, or of another salt of a weak acid of the alkali metals or alkaline earth metals, preferably of potassium, sodium, calcium or caesium. The addition of an organic base such as triethylamine, dimethylaniline, pyridine or quinoline or of an excess of the amine component of the formula II or of the alkylation derivative of the formula III may also be favourable.
Depending on the conditions used, the reaction time is between several minutes and 14 days, the reaction temperature is between approximately 0° and 1500, usually between 200 and 1300 Suitable inert solvents are, for example, hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether (methylglycol or ethylglycol) or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide, Nmethylpyrrolidone (NMP) or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the solvents mentioned.
'%VTO
29 The starting materials of the formulae II and III are generally known. Those which are novel, however, can be prepared by methods known per se.
Compounds of the formula I in which R 1 is O or O HN- N= 0 CH 3
R
3 and X together are thus forming a ring, Y is O, W is a bond, and R 2 and R 4 are as defined in Claim 1, can preferably be obtained by reacting compounds of the formula II in which Y is 0 with compounds of the formula IV in a Mitsunobu reaction in the presence of, for example, triphenylphosphine and diethylazo dicarboxylate in an inert solvent.
The starting materials of the formula II in which Y is 0, and those of the formula IV, are generally known.
Those which are novel, however, can be prepared by methods known per se.
Compounds of the formula I in which R is O o r
NO
HN-- N-= 0 CH,
R
3 and X together are thus forming a ring, 30 Y is -N N-, W is a bond,
R
4 is -[C(R 5 s 2 ],Ar or -[C(R 5 2 ]mHet, n [sic] is 0 and R 2 is as defined in Claim 1, can preferably be obtained by reacting compounds of the formula V with compounds of the formula VI.
In the compounds of the formula V L is preferably Cl, Br, I or a reactively modified OH group, such as, for example, an activated ester, an imidazolide or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy), or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).
The reaction of the compounds of the formula V with compounds of the formula VI is preferably carried out in an inert solvent and at temperatures as indicated above.
The starting materials of the formulae V and VI are generally known. Those which are novel, however, can be prepared by methods known per se.
Compounds of the formula I in which R is O or 'O HN-J N= 0 CH,
R
3 and X together are thus forming a ring, 31 Y is NR 5 -N N- N -N or
R
N N/ W is -CONH-, and R 2 and R 4 are as defined in Claim 1, can preferably be obtained by reacting compounds of the formula II in which R is 0 or HN- N O CH,
R
3 and X together are thus forming a ring, Y is NR 5 -N -N or
>"V-N
W is -CONH-, and R 2 and R 5 are as defined in Claim 1, with compounds of the formula VII.
The reaction of these compounds of the formula II in which W is -CONH- with compounds of the formula VII is preferably carried out in an inert solvent and at temperatures as indicated above.
32 The starting materials of the formula II in which W is -CONH- and of the formula VII are generally known.
Those which are novel, however, can be prepared by methods known per se.
Compounds of the formula I in which R 1 is 'N or HN4 N=* O CH 3
R
3 and X together are thus forming a ring, Y is N[C(RS) 2 ]m-COOR 5 W is SO 2 and R 2 and R 4 are as defined in Claim 1 can preferably be obtained by reacting compounds of the formula II in which
R
1 is O 'or N HN N= 0 CH,
R
3 and X together are thus forming a ring, Y is N[C(R 5 2 ]m-COOR and R 2 and R 5 are as defined in Claim 1, with compounds of the formula VIII.
In the compounds of the formula VIII, L is preferably Cl, Br, I or a reactively derivatized OH group, such as, for example, an activated ester, an imidazolide or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy having 6-10 C atoms (preferably phenyl or- p-tolylsulfonyloxy).
The reaction of the compounds of the formula II in which Y is N[C(R 5 2 ]m-COOR_ with compounds of the 33 formula VIII is preferably carried out in an inert solvent and at the temperatures given above.
Compounds of the formula I in which X is NH and
R
3 is H and R 2
R
4 Y and W are as defined in Claim 1, can be liberated from their oxazolidinone derivatives by treatment with a solvolysing or hydrogenolyzing agent. This is carried out under conditions like those described under "protective group removal".
Compounds of the formula I in which R 1 is -C(=NH)-NH 2 can furthermore be obtained from the corresponding cyano compound.
The conversion of a cyano group into an amidino group is carried out by reaction with, for example, hydroxylamine and subsequent reduction of the N-hydroxamidine with hydrogen in the presence of a catalyst, such as, for example, Pd/C.
To prepare an amidine of the formula I (R 1
NH
2 ammonia can also be added onto a nitrile of the formula I (R 1 CN). The addition is preferably carried out in several stages by a procedure in which, in a manner known per se, a) the nitrile is converted with
H
2 S into a thioamide, which is converted with an alkylating agent, for example CH 3 I, into the corresponding S-alkyl-imidothioester, which in turn reacts with NH 3 to give the amidine, b) the nitrile is converted with an alcohol, for example ethanol, in the presence of HC1 into the corresponding imidoester, and this is treated with ammonia, or c) the nitrile is reacted with lithium bis(trimethylsilyl)amide and the product is then hydrolysed.
Furthermore, it is possible to convert a compound of the formula I into another compound of the formula I by converting one or more radicals Y, R 1
R
2
R
3 and/or R 4 into one or more radicals Y, R 1
R
2
R
3 and/or R 4 for 34 example by acylating an amino group or reducing nitro groups (for example by hydrogenation over Raney nickel or Pd/carbon in an inert solvent, such as methanol or ethanol) to amino groups.
Esters can be hydrolysed, for example with acetic acid or with NaOH or KOH in water, water-THF or waterdioxane at temperatures between 0 and 1000.
It is furthermore possible to acylate free amino groups in a customary manner with an acyl chloride or acid anhydride or to alkylate with an unsubstituted or substituted alkyl halide, expediently in an inert solvent, such as dichloromethane or THF, and/or in the presence of a base, such as triethylamine or pyridine, at temperatures between -60 and +300 A base of the formula I can be converted into the associated acid addition salt with an acid, for example by reaction of equivalent amounts of the base and the acid in an inert solvent, such as ethanol, and subsequent evaporation. Acids which give physiologically acceptable salts are particularly suitable for this reaction. Thus, it is possible to use inorganic acids, for example sulfuric acid, nitric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, sulfaminic acid, or furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 1. benzenesulfonic acid, _p-toluenesulfonic acid, 11 -ptoueeslfni 0 35 naphthalene-mono- or -disulfonic acids and laurylsulfuric acid. Salts with physiologically unacceptable acids, for example picrates, can be used for isolation and/or purification of the compounds of the formula I.
On the other hand, compounds of the formula I can be converted with bases (for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate) into the corresponding metal, in particular alkali metal or alkaline earth metal salts or into the corresponding ammonium salts.
It is also possible to use physiologically acceptable organic bases, such as, for example, ethanolamine.
Owing to their molecular structure, the compounds of the formula I according to the invention can be chiral and can consequently be present in various enantiomeric forms. They may therefore be present in racemic or in optically active form.
Since the pharmaceutical activity of the racemates and/ or the stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates may be separated into enantiomeric compounds using chemical or physical means known to the person skilled in the art, or they may even be employed as such in the synthesis.
In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active separating agent. Suitable separating agents are, for example, optically active acids, such as the R- and S-forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N-benzoylproline or N-benzenesulfonylproline) or the various optically active camphorsulfonic acids.
S A chromatographic separation of the enantiomers can 36 also be advantageously carried out with the aid of an optically active separating agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other carbohydrate derivatives or chiral derivatized methacrylate polymers immobilized on silica gel).
Solvents which are suitable for this purpose are aqueous or alcoholic solvent mixtures, such as, for example, hexane/isopropanol/acetonitrile, for example in the ratio 82:15:3.
The invention furthermore provides the use of the compounds of the formula I and/or their physiologically acceptable salts for the preparation of pharmaceutical formulations, in particular by a non-chemical route.
For this purpose, they can be brought into a suitable dosage form together with at least one solid, liquid and/or semi-liquid carrier or auxiliary, and if appropriate in combination with one or more further active compounds.
The invention furthermore provides pharmaceutical formulations comprising at least one compound of the formula I and/or one of its physiologically acceptable salts.
These formulations can be used as medicaments in human or veterinary medicine. Possible carriers are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical administration and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates, such as lactose or starch, magnesium stearate, talc and petroleum jelly. Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used, in particular, for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, and 37 furthermore suspensions, emulsions or implants are used for parenteral administration, and ointments, creams or powders are used for topical administration. The novel compounds can also be lyophilized and the resulting lyophilisates can be used, for example, for the preparation of injection formulations. The formulations mentioned can be sterilized and/or comprise auxiliaries, such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, dyestuffs, flavourings and/or several further active compounds, for example one or more vitamins.
The compounds of the formula I and their physiologically acceptable salts can be employed for combating and preventing thromboembolic disorders, such as thrombosis, myocardial infarction, arteriosclerosis, inflammations, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens.
For this purpose, the substances according to the invention are usually preferably administered in dosages of between about 1 and 500 mg, in particular between 5 and 100 mg per dosage unit. The daily dosage is preferably between about 0.02 and 10 mg/kg of body weight. However, the specific dose for each patient depends on the most diverse factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, diet, on the administration time and route, and on the rate of excretion, medicament combination and severity of the particular disease to which the therapy applies. Oral administration is preferred.
All temperatures hereinabove and hereinbelow are given in 0 C. In the following examples, "customary work-up" means: water is added, if necessary, the pH is brought I\ to values of between 2 and 10, if necessary, depending 38 on the structure of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the organic phase is separated off, dried over sodium sulfate and evaporated and the residue is purified by chromatography over silica gel and/or crystallization.
Rf values are for silica gel; mobile phase: ethyl acetate/methanol 9:1.
Mass spectrometry (MS): El (electron impact ionization) M' FAB (fast atom bombardment) (M+H) Example 1 A solution of 100 mg of 3-[4-(5-methyl-[1,2,4]oxazolidin-2-one [obtainable by reaction of 3-[4- (5-methyl-[1,2,4]oxadiazol-3-yl)phenyl]-2-oxoxazolidinmethanesulphonate with 1-tertbutoxycarbonylpiperazine and sodium bicarbonate in acetonitrile; removal of the BOC group with HCl/dioxane and subsequent treatment with sodium hydroxide solution] and 110 mg of 2 ,4,6-trichlorobenzenesulphonyl chloride in 10 ml of dichloromethane is admixed with 400 mg of 4-dimethylaminopyridine on polystyrene and stirred at room temperature for 18 hours. The mixture is filtered and the solvent is removed, giving methyl-[1,2,4]-oxadiazol-3-yl)phenyl]5-[4-(24,6-trichlorophenylsulfonyl)piperazin-l-ylmethyl]oxazolidin-2one, FAB 586/588.
Similarly, reaction of "A" with 4-biphenylylsulfonyl chloride gives 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]-5- [4-(4-biphenylylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2-one; 39 with 2-phenylvinylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyll (2-phenylvinylsulfonyl) piperazin-1-ylmethyl] oxazolidin-2 -one; with 2-nitrophenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-nitrophenylsulfonyl) piperazin-1-ylmethyl] oxazolidin- 2-one; with 2,5-dimethoxyphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] 5-dimethoxyphenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2-one; with 2-naphthylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-naphthylsulfonyl)piperazin-1-ylmethylloxazolidin- 2-one; with 2-chloro-4-fluorophenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-chloro-4-fluorophenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2-one; with (2-acetamido-4-methylthiazol-5-yl) sulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] ((2-acetamido-4-methylthiazol-5-yl) sulfonyl) piperazin-l-ylmethyl] oxazolidin-2-one; with 2-cyanophenylsulfonyl. chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-cyanophenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2-one; with 5-nitro-2-methylphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (5-nitro-2-methylphenylsulfonyl)piperazix-1-ylmethyl] oxazolidin-2-one; S with benzylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-benzylsulfonylpiperazin-l-ylmethyl) oxazolidiri-2-one; with decylsulfonyl chloride gives 3-[4-(S-methyl-[l,2,4]-oxadiazol-3-yl)phenyl]-s- (4-decylsulfonylpiperazin-l-ylmethyl) oxazolidin-2-one; with 2-trifluoromethyiphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-trifluoromethylphenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2-one; with 3-chloro-4-fluorophenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3-chloro-4-fluorophenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2-one; with 4-chloro-2,5-dimethylphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-chloro-2, ylmethyl] oxazolidin-2 -one; with 2-f luorophenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-fluorophenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2 -one; with 3,4-dibromophenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3,4-dibromopherylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2 -one; with 3-chlorophenylsulfonyl chloride gives 41 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3-chlorophenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2 -one; with 2,6-dichlorophenylsulfonyl chloride gives 3- (5-methyl- [l,2,4]-oxadiazol-3-yl)phenyl] 6-dichlorophenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2 -one; with 3,4-dichlorophenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3,4-dichlorophenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2 -one; with 3,5-dichlorophenylsulfonyl chloride gives 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]-5- (3,5-dichlorophenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2-one; with 2-naphthylcarbonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-naphthylcarbonyl) piperazin-l-ylmethyl] oxazolidin- 2-one; with methylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-methylsulfonylpiperazin-l-ylmethyl) oxazolidin-2-one; with 2-methylsulfonyiphenylsulfonyl chloride gives 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]-5- (2-methylsulfonylphenylsulfonyl)piperazin-l-ylmethyll oxazolidin-2-one; with 2-nitrobenzylsulfonyl chloride gives 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]-5- (2-nitrobenzylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2 -one; 42 with (4-methoxycarbonyl-3-methoxythiophen-2-yl) sulfonyl chloride gives 3 [4 (5 -methyl 2, 4] -oxadiazol -3 -yl) phenyl]I -5 (4 -methoxycarbonyl-3 -methoxythiophen-2yl) sulf onyl) piperazin- 1-ylmethyll oxazolidin-2 -one; with 3-trifluoromethylphenylsulfonyl chloride gives 3 [4 (5 -methyl 1,2, 4] oxadiazol -3 -yl) pheniylI -5 (3-trifluoromethylphenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2-one; with 4-trifluoromethoxyphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-trifluoromethoxyphenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2-one; with (iS) -(camphor-10-yl) sulfoiyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] camphor- 10-yl) sulf onyl) piperazin- 1-ylmethyl] oxazolidin-2-one; with (lR) -(camphor-10-yl) sulfonyl chloride gives 3 [4 (5 -methyl 1, 2, 4] -oxadiazol -3 -yl) phenyl] (1R) camphor- 10 -yl) sul fonyl) piperazin- 1-ylmethyl] oxazolidin-2 -one; with 2, 5, 7, 8-pentamethylchroman- 6-yl) sulf onyl chloride gives 3 [4 (5 -methyl 1, 2, 4] -oxadiazol -3 -yl) phenyl] [4 2,5, 7, 8-pentamethyl chroman- 6-yl) sul fonyl) piperazin-1-ylmethyll oxazolidin-2-one; with 4-isopropylphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-isopropylphenylsulfonyl) piperazin-l-ylmethyl] oxazolidin-2-one; with 4-tert-butylphenylsulfonyl chloride gives 43 3- (5-methyl- -oxadiazol-3-yl)phenyl]1 (4-tert-butyiphenylsulfonyl) piperazin-1-ylmethyl] oxazolidin-2 -one; with 4-butyiphenylsulfonyl chloride gives 3 [4 (5 -methyl 1,2, 4] -oxadiazol 3-yl) phenyl] (4-butylphenylsulfonyl) piperazin-l-ylmethyl] oxazolidin-2 -one; with 3, 5-dinitro-4-methoxyphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3,5-dinitro-4-methoxyphenylsulfonyl)piperazin-lylmethyl] oxazol idin- 2-one; with ethylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-ethylsulfonylpiperazin-1-ylmethyl)oxazolidin-2-one; with 4-nitrophenylsulfonyl chloride gives 3 -methyl 2, 4]-oxadiazol 3-yl) phenyl]I- (4-nitropheriylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2 -one; with 2 -trifluoromethoxyphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-trifluoromethoxyphenylsulfonyl)piperazin-lylmethyl] oxazolidin-2-one; with 2,4-dinitrophenylsulfonyl chloride gives 3 -methyl 1,2, 4 ]-oxadiazol 3-yl) phenyl]I- (2,4-dinitrophenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2 -one; with isopropylsulfonyl chloride gives 3 (5-methyl- -oxadiazol-3-yl)phenyl] -sisopropylsulfonylpiperazin- 1-ylmethyl) oxazolidin-2one; with 4-ethylphenylsulfonyl chloride gives 44 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-ethylphenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2 -one; with 4-bromo-2-trifluoromethoxyphenylsulfonyl chloride gives 3 [4 (5 -methyl 1,2, 4] -oxadiazol 3-yl) phenyl] [4 (4 -bromo-2 -trif luoromethoxyphenylsulf oyl) piperazinl-ylmethyl] oxazolidiri-2-one; with 2,3, 4-trifluorophenylsulfonyl chloride gives 3 [4 (5 -methyl 2, 4] -oxadiazol -3 -yl) phenyl -5 (2,3,4-trifluorophenylsulfonyl)piperazin-lylmethyl] oxazolidin-2-one; with 3, 4-difluorophenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3,4-difluorophenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2 -one; with 2,2,2-trifluoroethylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2,2,2-trifluoroethylsulfonyl)piperazin-lylmethyl] oxazolidin- 2-one; with 3-nitro-4-methylphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3-nitro-4-methylphenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2 -one; with 2 -nitro- 6-chlorophenyl.sulf onyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-nitro-6-chlorophenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2-one; with 2,5-dimethoxyphenylace 'tyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] [4 5-dime thoxyphenyl ace tyl) piperazin- 1-ylmethyl] oxazolidin-2-one; 45 with 3,4-dichlorobenzoyl chloride gives 3- (5-methyl- [1,2,41 -oxadiazol-3-yl)phenyl] (3,4-dichlorobenzoyl)piperazin-l-ylmethyl] oxazolidin-2-one; with 3-f luorobenzoyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyll (3-fluorobenzoyl)piperazin-l-ylmethylloxazolidin-2one; with 4-trifluoromethoxybenzoyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-trifluoromethoxybenzoyl)piperazin-l-ylmethyl] oxazolidin-2-one; with 3-pyridylcarbonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3-pyridylcarbonyl)piperazin-1-ylmethylloxazolidin- 2-one; with 2-benzothienylcarbonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (2-benzothienylcarbonyl) piperazin-l-ylmethyl] oxazolidin-2-one; with 4-chlorophenylacetyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-chlorophenylacetyl) piperazin-l-ylmethyl] oxazolidin-2-one; with 1-naphthylcarbonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (l-naphthylcarbonyl)piperazin-l-ylmethylj oxazolidin- 2-one; with 3-benzodioxol-5-yl) carbonyl chloride gives 46 3- (5-methyl- -oxadiazol-3-yl)phenyl] ((1,3-benzodioxol-5-yl) carbonyl)piperazin-i-ylmethyl] oxazolidin-2-one; with 3-nitrobenzoyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3-nitrobenzoyl)piperazin-1-ylmethylloxazolidin-2 one; with 4-biphenylylcarbonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-biphenylylcarbonyl) piperazin-l-ylmethyl] oxazolidin-2 -one; with cyclopentylcarbonyl chloride gives 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]-5- (cyclopentylcarbonyl)piperazin-l-ylmethyl] oxazolidin-2 -one; with [5-chloro-l- (4-methylpheiyl) -lH-pyrazol-4-yl] sulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] [5-chloro-l- (4-methylphenyl) -1H-pyrazol-4yl) sulfonyllpiperazin-l-ylmethyl~oxazolidin-2-one; with 4-chlorophenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-chlorophenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2 -one; with 5,7,7-trimethyl-2-(1,3,3-trimethylbutyl)octylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] sulfonyl] piperazin-l-ylmethyl }oxazolidin-2-one; with 2-butoxy-5- 1-dime thylpropyl) phenyl sul fonyl chloride gives -47 3- (5-methyl- -oxadiazol-3-yl)phenyl] [2-butoxy-5- (1,1-dimethylpropyl)phenylsulfoiyl] piperazin-l-ylmethyl }oxazolidin-2-one; with 2-butoxy-5- (1,l1,3, 3-tetramethylbutyl)pheiylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl]1 [2-butoxy-5- 3-tetramethylbutyl)phenylsulfonyllpiperazin-l-ylmethyl~oxazolidin-2-one; with 2-nitro-4-trifluoromethylphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl]1 (2 -nitro- 4 -tri fluoromethylphenyl sul fonyl) piperazinl-ylmethyl] oxazolidin-2-one; with 4-bromo-2-ethylpheriylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)pheiyl] (4-bromo-2-ethylpherlylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2-oie; with 4-trifluoromethylphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-trifluoromethylphernylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2-oie; with 4-trifluoromethylphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-trifluoromethylpheriylsulfonyl)piperazin-1-ylmethyl] oxazolidiri-2-one; with 3, 4-difluorophenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] 3 ,4-dif luorophenylsulfonyl) piperazin-1-ylmethyl] oxazolidin-2 -one; with l-naphthylsulfonyl chloride gives 3 -(5methyl 1,2, 4] -oxadiazol-3 yl) phenyl -5 (l-naphthylsulfonyl)piperazinl1ylmethylloxazolidin- 2-one;
C'
Qz-O yo 48 with 4-methoxyphenylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-methoxyphenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2-one; with 4-tolylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-tolylsulfonyl)piperazin-l-ylmethylloxazolidin-2one; with 4-propylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-propylsulfonyl)piperazin-l-ylmethylloxazolidin-2one; with 6-chloro-2-naphthylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (6-chloro-2-naphthylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2 -one; with 2- (naphth-1-yl) ethylsulfonyl chloride gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (naphth-1-yl)ethylsulfonyl~piperazin-iylmethyl }oxazolidin-2-one; with isobutyl chloroformate gives 3-[4-(5-methyl- [l,2,4]-oxadiazol-3-yl)phenyl]-5- [4-isobutyloxycarbonyl)piperazin-1-ylmethyl] oxazolidin- 2-one.
Example 2 A solution of 100 rrg of 3- (5-methyl- [1,2,41 oxadiazol-3-yl)phenyl] (2,4,6-trichlorophenylsulf onyl) piperazin-l-ylmethyl] oxazolidin-2 -one in 15 ml of methanol is admixed with 100 mg of Raney nickel and a drop of -acetic acid and hydrogenated at room temperature for 8 hours. The catalyst is filtered off and the solvent is removed. This gives 4-{2-oxo-5- [4- 49 (2,4,6-trichlorophenylsulfonyl)piperazin-lylmethyl] oxazolidin-3-yllbenzamidine, acetate, FAD 546/548.
Similarly, the benzamidine derivatives below are obtained f rom the compounds obtained in Example 1 by hydrogenation 4-{2-oxo-5- (4-biphenylylsulfonyl)piperazin-lylmethylloxazolidin-3-yl~benzamidine, trifluoroacetate, FAD 520; 4-{2-oxo-5- (2-phenylethylsulfonyl)piperazin-lylmethyl] oxazolidin-3-yl~benzamidine, trifluoroacetate, FAB 472; 4-{2-oxo-5- (2-aminophenylsulfonyl)piperazin-iylmethyl] oxazolidin-3-yllbenzamidine, trifluoroacetate, FAB 459; 4-{2-oxo-5- (2,5-dimethoxyphenylsulfonyl) piperazin-1-ylmethyl] oxazolidin-3-yllbenzamidine, trifluoroacetate, FAB 504; 4-{2-oxo-5- (2-naphthylsulfonyl)piperazin-iylmethyllloxazolidin-3-yl~benzamidine, trifluoroacetate, FAB 494; 4-{2-oxo-5- (2-chloro-4-fluorophenylsulfonyl) piperazin-1-ylmethylloxazolidin-3-yllbenzamidine, trifluoroacetate, FAB 496; 4-{2-oxo-5- [4-((2-acetamido-4-methylthiazol-5-yl)sulfonyl)piperazin-1-ylmethylloxazolidin-3-yl}benzamidine, trifluoroacetate, FAB 522; 4-{2-oxo-5-[4- (2-cyanophenylsulfonyl)piperazin-lylmethyl] oxazolidin-3-yl }benzamidine, trifluoroacetate, FAB 469; 50 4-{2-oxo-5- amino -2-methylphenylsulfonyl) piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidine, trifluoroacetate, FAB 473; 4-{2-oxo-5- (4-benzylsulfonylpiperazii-lylmethylloxazolidin-3-yl~benzamidine, trifluoroacetate, FAB 458; 4 -{f2 -oxo 5- (4 -decyl sul fonylpiperaz in -1 ylmethyl] oxazolidii-3-yl~beizamidiie, trifluoroacetate, FAB 508; 4 -{(2-oxo 5- 4 (2 tri fluoromethylphenyl sul fonyl) pipera z in 1- ymethyl ]oxa zol idin 3- y1Ibenzami dine, trifluoroacetate, FAB 512; 4 -f2 oxo 4 -chl oro -4 fluorophenyl sul fonyl) piperazii- 1 -ylmethyl I oxazol idin- 3-yl) benzamidiie, trifluoroacetate, FAB 496; 4-{12 -oxo- 5- [4 -chloro 5-dimethylpheiyl sul f oryl) piperazin- 1 -ylmethyl]I oxazol idii- 3 -yl benzamidiie, trifluoroacetate, FAB 506; 4 5- [4 (2 -f luorophenyl sulf oryl) piperazin-1 ylmethylloxazolidin-3-yllbenzamidine, acetate, FAB 462; 4 -oxo 5- 4 4 -dibromophenyl sul fonyl) pipera zin- 1 yme thyl Ioxa zoli din -3 -yl) benzami dine, trifluoroacetate, FAB 600/602/604; 4 -oxo -5 4- (3 -chl orophenyl sul fonyl) pipe raz in -1 ylmethyl] oxazolidin-3-yllbenzamidine, trifluoroacetate, FAB 478; 4-{2-oxo-5-14- (2,6-dichiorophenylsulfonyl) piperazin-1-ylmethyll oxazolidin-3-yllbenzamidine, trifluoroacetate, FAB 512;
LL,
oo/r 51 4-{2-oxo-5- (3,4-dichloropheriylsulfonyl) piperazin-1-ylnethyl] oxazolidin-3-yl~benzamidiie, trifluoroacetate, FAD 512; 4-{2-oxo-5- (3,5-dichlorophenylsulfonyl) piperazin-1-ylmethyl] oxazolidin-3-yllbeizamidine, acetate, FAB 512; 4 5- [4 (2 -naphthylcarbonyl) piperazin- 1ylmethylloxazolidin-3-yl~benzanidine, acetate, FAB 458;.
4- {2-oxo-5- (4-methylsulfonylpiperazin-lylmethyl] oxazolidin-3-yllbenzamidiie, acetate, FAB 382; 4 -oxo- 5- [4 (2 -methylsul fonylphenylsul fonyl) piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidine, acetate, FAB 522; 4-{2-oxo-5- (2-aminobenzylsulforiyl)piperazin-lylmethyl] oxazolidin-3-yl~benzaridine, acetate, FAB 473; -oxo 5- [4 (4 -methoxycarbonyl 3-methoxythio pheri-2-yi) sulfonyi)piperazin-1-ylmethylloxazolidin-3yllbenzamidine, acetate, FAB 538; 4-{2-oxo-5- (3-trifluoromethylpheriylsulfonyl) piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidine, acetate, FAB 512; 4 -oxo -5 [4 (4 -t ri fluoromethoxyphenyl sul fonyl) piperazin-1-ylnethyl] oxazoiidin-3-yllbenzanidine, acetate, FAB 528; 4 (2 -oxo -5 [4 camnphor- 10 -yl) sul fonyl) piperazin-1-ylmethylloxazolidin-3-yi~benzamidine, acetate, FAR 518; 52 4-{2-oxo-5- -camphor--10-yl) sulfonyl) piperazin- 1-ylmethyl] oxazol idin- 3-yl }benzamidine, acetate, FAB 518; 4-{2-oxo-5-[4-((2,2,5,7,8-pentamethylchroman-6yl) sulfonyl)piperazin-1-ylmethylloxazolidin-3-yl}benzamidine, acetate, FAB 570; 4-{2-oxo-5-[4-(4-isopropylpheiylsulfonyl)piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidine, acetate, FAB 486; 4-{2-oxo-5-[14- (4-tert-butyiphenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-3-yllbenzamidine, acetate; 4-{2-oxo-5- (4-butylphenylsulfonyl)piperazin-iylmethylloxazolidin-3-yl~benzamidine, acetate, FAB 500; 4-{2-oxo-5- (3,5-diamino-4-methoxyphenylsulfonyl) piperazin- 1-ylmethyl] oxazolidin-3 -yl benzamidine, acetate, FAB 504; 4-{2-oxo-5- (4-ethylsulfonylpiperazin-1-y1methyl]oxazolidin-3-yllbenzamidine, acetate, FAD 396; 4-{2-oxo-5- (4-nitrophenylsulfonyl)piperazin-lylmethylloxazolidin-3-yllbenzamidine, acetate, FAB 459; 4-{2-oxo-5- (2-trifluoromethoxyphenylsulfonyl) piperazin-1-ylnethyl] oxazolidin-3-yl~benzamidine, trifluoroacetate, FAD 528; 4-{2-oxo-5- (2,4-diaminophenylsulfonyl)piperazin-1-ylmethylloxazolidin-3-yl~benzamidine, acetate, FAD 474; 4-{2-oxo-5- 4 -isopropylsulfonylpiperazin-i- Sylmethyl]oxazolidin-3-yllbenzamidine, acetate, FAD 410; 53 4-{2-oxo-5- (4-ethylphenylsulfonyl)piperazin-lylmethyl] oxazolidin-3-yl~benzamidine, trifluoroacetate, FAB 472; 4-{2-oxo-5- (4-bromo-2-trifluoromethoxyphenylsulfonyl)piperazin-1-ylmethylloxazolidin-3-yl}benzamidine, acetate, FAB 606/608; 4-{2-oxo-5-[4-(2,3,4-trifluorophenylsulfoiyl)piperazin-1-ylmethyl] oxazolidiri-3-yllbenzamidine, acetate, FAB 498; -oxo 5- 4- 4 -di fluorophenyl sul f oyl) piperaziri-1-ylmethylloxazolidin-3-yl~benzamidine, acetate, FAB 480; 4-{2-oxo-5- (2,2,2-trifluoroethylsulfonyl) piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidiie, trifluoroacetate, FAB 450; 4-{2-oxo-5-[4-(3-amino-4-methylpheiylsulfoiyl)piperazin-1-ylmethyl] oxazolidin-3-yllbenzamidine, trifluoroacetate, FAB 473; 4-{2-oxo-5- (2-amino-6-chlorophenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidine, trifluoroacetate, FAB 585; 4-{2-oxo-5- (2,5-dimethoxypheriylacetyl) piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidine, acetate, FAB 482; 4-{2-oxo-5- (3,4-dichlorobenzoyl)piperazin-1ylmethylloxazolidin-3-yl~beinzamidine, acetate, FAB 476;
RA
54 4-{2.-oxo-5- (3-f luorobenzoyl)piperazij-1ylmethylloxazolidin-3-yllbenzanidine, acetate, FAD 426; 4-{2-oxo-5- (4-trifluoromethoxybenzoyl) piperazin-1-ylmethyl] oxazolidii-3-yl~beizamidiie, acetate, FAB 492; 4-{2-oxo-5- (3-pyridylcarboriyl)piperazin-lylrethylloxazolidin-3-yl~benzamidine, acetate, FAB 409; 4-{2-oxo-5- (2-benzothienylcarbonyl)piperazin-iylrethylloxazolidin-3-yl~benzamidine, acetate, FAB 463; 4-{2-oxo-5- (4-chlorophenylacetyl)piperazin-lylmethylloxazolidin-3-yl~beizamidine, acetate, FAB 456; 4-{2-oxo-5- (1-naphthylcarbonyl)piperazin-iylmethylloxazolidin-3-yllbenzamidine, acetate, FAB 458; 4-{2-oxo-5-[4-((1,3-benzodioxol-5-yl)carbonyl)piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidiie, acetate, FAB 452; 4-{2-oxo-5- (3-amirobenzoyl)piperazin-1-ylmethylloxazolidin-3-yllbenzamidine, acetate, FAD 423; 4-{2-oxo-5- (4-biphenylylcarbonyl)piperazii-lylrethylloxazolidin-3-yl~benzamidine, acetate, FAB 484; 4-{2-oxo-5- (cyclopentylcarbonyl)piperazii-lylmethylloxazolidin-3-yl~benzamidine, acetate, FAB 400; 4-{2-oxo-5-{4- [5-chloro-l- (4-methylphenyl) -lHpyrazol-4-yl) sulfonyllpiperazin-1-ylmethylloxazolidin- 3-yllbenzamidiie, acetate, FAB 558; 4-{2--oxo-5- (4-chloropheriylsulfonyl)piperazin-lylmethyl] oxazolidin-3-yl~benzamidine, trifluoroacetate, FAB 478; 55 4-{2-oxo-5-{4- [5,7,7-trinethyl-2- (1,3,3-trimethylbutyl) octyl sul f onyl] piperazin- 1-ylmethyl }oxazol idin- 3yl~benzamidine, trifluoroacetate, FAD 620; 4-{2-oxo-5-{4- [2-butoxy-5-(1,1-dimethylpropyl) phenylsulfonyl] piperazin-1-ylmethylloxazolidin-3yl~benzamidine, trifluoroacetate, FAB 586; 4-{2-oxo-5-{4- [2-butoxy-5-(1,1,3,3-tetramethylbutyl)phenylsulfonyl] piperazin-1-ylmethylloxazolidin-3yl~benzamidine, trifluoroacetate, FAB 628; 4-{2-oxo-5- (2 -amino- 4-trif luoromethylphenyl sulfonyl)piperazin-1-ylmethylloxazolidin-3yl~benzamidine, trifluoroacetate; 4 -{f2 -oxo 5-[4 -broro 2 -ethylphenyl sul fonyl) piperazii- 1 -ylmethyl]I oxazol idin- 3-yl) benzamidine, trifluoroacetate, FAB 550/552; 4 -{f2 -oxo -5 [4 (4 -tri fluoromethylphenyl sul f oyl) piperazin- 1-ylmethyl]I oxazol idin- 3-yl Ibenzamidine, acetate, FAB 512; -oxo -5 [4 (6 -chloro- 2-naphthyl sul fonyl) piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidine, acetate, FAB 528; 4-{f2-oxo-5- (isobutyloxycarbonyl)piperazin-1ylmethylloxazolidin-3-yl~benzamidine, acetate, FAB 404.
Similarly, reaction of 3-[3-(5-rnethyl- [1,2,4]-oxadiazol-3-yl)phenyl] -5-piperazin-1-ylmethyloxazolidin- 2-one with 6-chloro-2-naphthylsulfonyl chloride and subsequent hydrogenation gives the compound 56 3-{2-oxo-5- (6-chloro-2-naphthylsulfonyl).
piperazin-l-ylmethylloxazolidin-3-yllbenzamidine, m.p.
118 0
C.
Similarly, reaction of 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl] -5-piperazin-1-ylmethyloxazolidin-2one with 6-methoxy-2-naphthylsulfonyl chloride and subsequent hydrogenation gives the compound 4-{2-oxo-5-[4-(6-methoxy-2-naphthylsulfonyl)piperazin-1-ylmethyl] oxazolidin-3-yl~benzamidine.
Similarly, reaction of 3- (5-methyl- [l,2,4]-oxadiazol-3-yl)phenyl] -5-piperazin-l-ylmethyloxazolidin-2one with 2-f luorobenzyl chloride and subsequent hydrogenation gives the compound 4 -f luorobenzyl) piperazin- 1-yl methyl] oxazolidin-3 -yl }benzamidine.
Example 3 A solution of 100 mg of 3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl] (2,4,6-trichlorophenylsulf onyl) piperazin-1-ylmethyl] oxazolidin-2 -one in 8 ml of methanol is admixed with 3 ml of lN aqueous sodium hydroxide solution and stirred at 600 for 48 hours.
This gives, after customary work-up, 3-[4-(5-methyl- [1,2,4]-oxadiazol-3-yl)phenylamino]-l- (2,6-dichloro- 4-methoxyphenylsulfonyl) piperazin-l-yl] propan-2-ol, FAB 556/558.
Similarly, 3 -[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenylps5-[4- 3 ,4-difluorophenylsulfonyl)piperazin-1-ylmethyjj oxazolidin-2-one gives 57 3 (5-methyl- -oxadiazol-3-yl)phenyl.
amino] (3-f luoro-4-methoxyphenylsulfonyl) piperazin-l-yl] propan-2-ol; 3 -methyl 1,2, 4]-oxadiazol -3 -yl) phenyl 5 4-.(l naphthylsul fonyl) piperazin-l1-ylmethyl]I oxazol idin-2 -one gives 3- (5-methyl- -oxadiazol-3-yl) -phenylamino] 1- [4 (l -naphthylsul fonyl) piperazin-l1-yl Ipropan- 2-ol; 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4trifluoromethylphenylsulfonyl)piperazinl1ylmethyl] oxazolidin-2-one gives 3 (5-methyl- [1,2,4 -oxadiazol-3-yl)phenylamino] (4-trifluoromethylphenylsulfonyl)piperazinl-yl] propan-2-ol; 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4biphenylylsulfonyl)piperazin-l-ylmethylloxazolidin-2 one gives 3 (5-methyl- -oxadiazol-3-yl)phenylamino] (4-biphenylylsulfonyl)piperazin-lyl] propan-2-ol; 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3trifluoromethylphenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2-one gives 3 (5-methyl- -oxadiazol-3-yl)phenylamino] 3 -trifluoromethylphenylsulfonyl)piperazinl-yl] propan-2-ol; 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4tri fluoromethoxyphenylsul fonyl) piperazin-l1-ylmethyl]I oxazolidin-2-one gives 3 -methyl 2, 41oxadiazol -3 -yl) phenylamino] 1- (4-trifluoromethoxyphenylsulfonyl)piperazin-l yl] propan-2-ol; 58 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4isopropylphenylsulfonyl)piperazin-1-ylmethyl] oxazolidin-2-one gives 3-[4-(5-methyl-[l,2,4]-oxadiazol-3-yl)phenylp amino] (4-isopropylphenylsulfonyl)piperazin-lyl] propan-2 -ol; 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4butylphenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2one gives 3- (5-methyl- -oxadiazol-3-yl)phenylamino] (4-butylphenylsulfonyl) piperazin-lyl] propanol-2-ol; 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]-5-[4-(4methoxyphenylsulfonyl)piperazin-l-ylmethyl] oxazolidin- 2-one gives 3-[4-(5-rnethyl-[l,2,4]-oxadiazol-3-yl)phenylamino] (4-methoxyphenylsulforiyl)piperazin-l-yl] propan-2-ol; 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4tolylsulfonyl) piperazin-l-ylmethyl] oxazolidin-2-one gives 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenylamino] (4-tolylsulfonyl)piperazin-l-yllpropan-2ol; 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4propylphenylsulfonyl)piperazin-l-ylmethyl] oxazolidin-2one gives 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenylamino] (4-propylphenylsulfonyl)piperazin-l-yl] propan-2-ol; 3- (5-methyl- -oxadiazol-3-yl)phenyl] (6chloro-2-naphthylsulfonyl)piperazin-1-ylmethy1] oxazolidin-2-one gives 59 3- (5-methyl- -oxadiazol-3-yl)phenylamino] (6-chloro-2-naphthylsulfonyl)piperazin-iyl] propan-2 -ol; 3-[4-(5-methyl-[l,2,4]-oxadiazol-3-yl)phenyl]-5.[4-(2phenylvinylsulfonyl)piperazin-1-ylnethyl] oxazolidin-2one gives 3 [4 (5 -methyl 1,2, 4] -oxadiazol -3 -yl) phenyl amino] (2-phenylvinylsulfonyl)piperazin-lyllpropan-2-ol; 3 [4 (5 -methyl 1,2, 4] -oxadiazol 3-yl) phenyl] -5 [2 (naphth-l-yl) ethyl sulfonyl] piperazin-1-ylmethyl oxazolidin-2-one gives 3 -methyl 1,2, 41-oxadiazol -3 -yl) phenyl amino] (naphth-l-yl)ethylsulfonyllpiperazin-lyl~propan-2 -01.
Similarly, 4-{2-oxo-5- (6-methoxy-2-naphthylsulfonyl)piperazin-l-ylmethyl] oxazolidin-3-yl~benzamidine gives the compound 4-{2-hydroxy-3- (6-methoxynaphthalene-2sulfonyl) piperazin-l-yl] propylamino~benzamidine, diacetate, FAB 498 and 4-{2-oxo-5- (2-fluorobenzyl)piperazin-1-ylmethyl] oxazolidin-3-yl }benzamidine gives the compound 4 -{(2-hydroxy- 3- [4 (2 -f luorobenzyl) piperazin-l1-yl] propylamino~benzamidine, acetate, FAB 386.
Example 4 A solution of 60 mg of 3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenylamino (2,6-dichloro-4methoxyphenylsulfonyl)piperazin1-ylpropan2ol in ml of methanol is admixed with 50 mg of Raney nickel and a drop of acetic acid and hydrogenated at room 60 temperature for 8 hours. The catalyst is filtered off and the solvent is removed. This gives dichloro-4-methoxyphenylsulfonyl)piperazin-l-yl] -2hydroxypropylaminolbenzamidine, acetate, FAB 516/518.
Similarly, the compounds below are obtained from the propan-2-ol derivatives listed under Example 3 by hydrogenation fluoro 4 -ethoxyphenyl sul fonyl) piperazin-l-yl] 2 -hydroxypropyl amino) benzamidine, acetate, FAB 466; (1-naphthylsulfonyl)piperazin-1-ylI -2hydroxypropyl amino Ibenzamidine, acetate, FAB 468; (4-trifluoromethylphenylsulfonyl) piperazin-1-yl] 2 -hydroxypropyl amino Ibenzamidine, acetate, FAB 486; (4-biphenylylsulfonyl)piperazin-1-ylI -2hydroxypropyl amino) benzamidine, acetate, FAB 494; (3-trifluoromethylphenylsulfonyl) piperazin-1-yl] 2-hydroxypropyl amino Ibenzamidine, acetate, FAB 486; 4- (4 -t ri fluoromethoxyphenyl sul fonyl) piperazin-l-yl] 2 -hydroxypropyl amino) benzamidine, acetate, FAB 502; (4-isopropylphenylsulfonyl)piperazin-lyl] 2 -hydroxypropyl amino) benzamidine, acetate, FAB 460; (4-butylphenylsulfonyl)piperazinl1yl] -2hydroxypropyl amino Ibenzami dine, acetate, FAB 474; (4-methoxyphenylsulfonyl)piperazin-1-yl] 2-hydroxypropyl amino) benzami dine, acetate, FAB 448; 61 (4-tolylsulfonyl)piperazin-l-yl]1-2hydroxypropylamino~benzamidine, acetate, FAB 432; 4 [4 (4 -propylphenylsulf onyl) piperazin-l1-yl -2 hydroxypropylamino~benzamidine, acetate, FAB 460; 4 [4 (6 -chloro- 2-naphthylsul fonyl) piperazinyl] -2-hydroxypropylamino~benzamidine, acetate, FAB 502; 4 [4 (2 -phenylvinylsul fonyl) piperazin-l1-yl -2 hydroxypropylaminolbenzamidine, acetate, FAB 446; (naphth-l-yl)ethylsulfonyllpiperazin-lyl}-2-hydroxypropylamino~benzanidine, acetate, FAB 496.
Example A solution of 10.0 g of methyl {3-[4-(5-methyl-[l,2,4]oxadiazol-3-yl)phenyl] sulfonate, 6.73 g of 4-BOC-aminopiperidine and 8.5 g of sodium bicarbonate in 200 ml of acetonitrile is heated under ref lux for 40 hours. Customary work-up gives 5- (4-BOC-arninopiperidin-l-ylmethyl) methyl- -oxadiazol-3-yl)phenylloxazolidin-2-one.
The BOC group is cleaved off using TFA in dichloromethane, giving 5- (4-aminopiperidin-l-ylmethyl)-3-[4-(5-methyl-[l,2,4]-oxadiazol.3-yl)phenyl]oxazolidin-2-one Similarly to Example 1, reaction of "B" with (3-methoxy-4-methoxycarbonylthiophen2yl) sulfonyl chloride gives N- (5-methyl- -oxadiazol-3-yl) phenyl] 2 -oxooxazolidin-5-ylmethyllpiperidin4yl) (3- -i ethoxy-4-methoxycarbonylthiophen-2-yl) sulfonamide PC
I
62 0with benzenesulfonyl chloride gives N-(l-{3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyll -2-oxooxazolidin--5-ylmethyl~piperidin-4-yl) benzenesulfonamide; with 3,4-dimethoxybenzenesulfonyl chloride gives 3,4-dimethoxy-N-(l-{3-[4-(5-methyl-[l,2,4]oxadiazol-3-yl)phenyl] piperidin-4-yl) benzenesulfonamide; with butylsulfonyl chloride gives N-(l-{3-[4-(5-methyl-[l,2,41-oxadiazol-3-yl)phenyl] -2-oxooxazolidin-5-ylmethyl~piperidin-4-yl) butyl sulfonamide; with 2,4, 6-trimethylbenzenesulfonyl chloride gives 2,4,6-trimethyl-N-(l-{3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyll piperidin-4-yl) benzenesulfonamide; with phenylvinylsulfonyl chloride gives phenylvinyl-N-(l-{3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl] piperidin-4-yl) sulfonamide; with 2 -methylsulfonylbenzenesulfonyl chloride gives 2-methylsulfonyl-N-(l-{3-[4-(5-methyl-[1,2,41oxadiazol-3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl piperidin-4-yl) benzenesulfonamide; with 4-biphenyly-isulfonyl chloride gives 63 4 -biphenylyl [4 (5 -methyl 1,2, 4] oxadiazol 3-yl) phenyl]I 2- oxooxazol idin- piperidin-4 -yl) sulfonamide; with 5-dimethylamino-l-naphthylsulfonyl chloride gives (5-methyl- oxadiazol-3-yl)phenyl] -2-oxooxazolidin-5-ylmethyl} piperidin-4-yl) -l-naphthylsulfonamide; with l-naphthylsulfonyl chloride gives N- (5-methyl- -oxadiazol-3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl~piperidin-4-yl) -1naphthyl sulfonamide.
By hydrogenation similarly to Example 2, these give the compounds below 4 (3 -methoxy- 4-methoxycarbonylthiophen-2 yl) sul fonylamino) piperidin-l1-ylmethyl] -2-oxooxazol idin- 3-yl~benzamidine, acetate, FAB 552; 4 [4 (benzenesul fonylamino) piperidin-l1-yl methyl] -2-oxooxazolidin-3-yllbenzamidine, acetate, FAB 458; 4 [4 4-dimethoxybenzenesulf onyl amino) piperidin-l-ylmethyl] -2-oxooxazolidin-3yl~benzamidine, acetate, FAB 518; (butylsulfonylamino)piperidin-l-ylmethyl] 2-oxooxazolidin-3-yl~benzamidine, acetate, FAB 438; 6 -trimethylbenzenesul fonyl amino) piperidin-l-ylmethyl] 2 -oxooxazolidin-3-yllbenzamidine, acetate, FAB 500; 4 [4 (phenyl ethyl su f onylamino) piperidinylmethyl] -2-oxooxazolidin-3-yl~benzamidine, acetate, FAB 486; 64 (2-methylsulfonylbenzenesulfonylamino) piperidin-1-ylmethyl] -2-oxooxazolidin-3-yllbenzamidine, acetate, FAB 536; (4-biphenylylsulfonylamino)piperidin-lylmethyl] -2-oxooxazolidin-3-yl~benzamidine, acetate, FAB 533; amino) piperidin-l-ylmethyl] -2-oxooxazolidin-3yl~benzamidine, acetate, FAB 551; (l-naphthylsulfonylamino)piperidin-l-ylmethyl] -2-oxooxazolidin-3-yllbenzamidine, acetate, FAB 458.
Example 6 A solut ion of 10. 0 g of methyl (3 -methyl 2, 4]oxadiazol-3-yl)phenyl] sulfonate, 7.4 g of N,N'-dimethylethylenediamine and g of sodium bicarbonate in 400 ml of acetonitrile is heated under ref lux. for 40 hours. Customary work-up gives [methyl- (2-methylaminoethyl)aminolmethyl}-3- (5-methyl- -oxadiazol-3-yl)phenylloxazolidin- 2-one Np\ 0 Similarly to Example 1, reaction of "C" with 2,4, 6-trichlorophenylsulfonyl chloride gives 2,4,6-trichloro-N-methyl-N-[2-(methyl{(3 methyl- -oxadiazol-3-yl)phenyl] -2-oxooxazolidin- }amino) ethyl] benzenesulfonamide 65 -N 0 CI a 01 with 2-trifluoromethoxypheiylsulfonyl chloride gives 2-trifluoromethoxy-N-methyl-N- (methyl-{3- methyl- -oxadiazol-3-yl)phenyl] -2-oxooxazolidin- -ylmethyl }amino) ethyl] benzenesulfonamide; with 2,4, 6-trichlorophenylsulfonyl chloride gives 2,4,6-trichloro-N-methyl-N- (methyl-{3- methyl- -oxadiazol-3-yl)pheiyl]I -2-oxooxazolidinamino) ethyl] benzenesulfonamide; with 4 -trifluoromethylphenylsulfonyl chloride gives 4-trifluoromethyl-N-methyl-N- (methyl-{3- methyl- -oxadiazol-3-yl)phenyl] -2-oxooxazolidinlamino) ethyl] benzenesulfonamide; with 4-isopropylphenylsulfonyl chloride gives 4-isopropyl-N-methyl-N- (methyl-{3- [1,2,43 -oxadiazol-3-yl)phenyl] ylmethyl }amino) ethyl] benzenesulfonamide; with 4 -propylphenylsulfonyl chloride gives 4-propyl-N-methyl-N- (methyl-{3- -oxadiazol-3-yl)phenyl] ylmethyl }amino) ethyl] benzenesulfonamide; with 4-acetamidophenylsulfonyl chloride gives 4-acetamido-N-methyl-N- (methyl-{3- -oxadiazol-3-yl)phenyl] ylmethyl }amino) ethyl] benzenesulfonamide; with 2-naphthylsulfonyl chloride gives 66 N-methyl-N- (methyl-{3- (5-methyl- oxadiazol-3-yl)phenyl] ylmethyl~amino) ethyl] -2-naphthylsulfonamide; with 3-trifluoromethylphenylsulfonyl chloride gives 3-trifluoromethyl-N-methyl-N- (methyl-{3- methyl- -oxadiazol-3-yl)phenyl] -2-oxooxazolidin- }amino) ethyl] benzenesulfonamide; with 4-chloro-3-nitrophenylsulfonyl chloride gives 4-chloro-3-nitro-N-methyl-N- (methyl-{3- methyl- -oxadiazol-3-yl)phenyl] -2-oxooxazolidin- -ylmethyl }amino) ethyl] benzenesulfonamide; with phenylvinylsulfonyl chloride gives N-methyl-N- (methyl-{3- (5-methyl- oxadiazol-3-yl)phenyl] ylmethyl} amino) ethyl] phenylvinylsulfonamide; with benzylsulfonyl chloride gives 4-trifluoromethyl-N-methyl-N- (methyl-{3- methyl- -oxadiazol-3-yl)phenyl] -2-oxooxazolidin- }amino) ethyl] benzyl sulfonamide; with tolylsulfonyl chloride gives 4-methyl-N-methyl-N- (methyl-{3- -oxadiazol-3-yl)phenyl] ylmethyl }amino) ethyl] benzenesul fonamide; with 4-methoxyphenylsulfonyl chloride gives 4-methoxy-N-methyl-N- (methyl-{3- -oxadiazol-3-yl)phenyl] ylmethyl }amino) ethyl] benzenesulfonamide; with l-naphthylsulfonyl chloride gives N-methyl-N- (methyl-{3- (5-methyl- oxadiazol -yl)phenyl] ylmethyliamino) ethyl] -l-naphthylsulfonamide; 67 with 4-biphenylylsulfonyl chloride gives N-methyl-N- (methyl-{3- (5-methyl- oxadiazol-3-yl)phenyl] ylmethyliamino) ethyl] -4-bipheriylylsulfonamide; with 3,4-difluorophenylsulfonyl chloride gives 3,4-difluoro-N-methyl-N- (methyl-{3- methyl- -oxadiazol-3-yl)phenyl] -2-oxooxazolidinlamino) ethyl] benzenesulfoiamide; with 4-pentylphenylsulfonyl chloride gives 4-pentyl-N-methyl-N- (methyl-{3- [1,2,4]-oxadiazol-3-yl)phenyl]-2-oxooxazolidii-5ylmethyl }amino) ethyl] benzenesulfonamide; with 4-butylphenylsulfonyl chloride gives 4-butyl-N-methyl-N- (methyl-{3- -oxadiazol-3-yl)phenyl] ylmethyl }amino) ethyl] benzenesulfonamide; with 4-methylsulfonylphenylsulfonyl chloride gives 4-methylsulfonyl-N-methyl-N- (methyl-{3- methyl- -oxadiazol-3-yl)phenyl] -2-oxooxazolidin- -ylmethyl }amino) ethyl] benzenesul fonamide; with 6-chloro-2-naphthylsulfonyl chloride gives 6-chloro-N-methyl-N- (methyl-{3- [l,2,4]-oxadiazol-3-yl)phenyl]-2-oxooxazolidin-5ylmethyl} amino) ethyl] -2-naphthylsulfonamide; By hydrogenation similarly to Example 2, these give the compounds below 4-{5-[(methyl-{2-[methyl-(2,4,6-trichlorobenzenesulfonyl)aminolethyliamino)methyl] -2-oxooxazolidin-3yl~benzamidine, trifluoroacetate, FAB 548/550 68 HN N'10
CI
Ci
CI
[(methyl-{2- [methyl- (2-trifluoromethoxybenzenesulfonyl) amino] ethyl~amino)methyl] -2-oxooxazolidin-3-yl~benzamidine, acetate, FAB 530; [(methyl-{2- [methyl- (4-trifluoromethylbenzenesulfonyl) amino] ethyl~amino)methyl] -2oxooxazolidin-3-yl~benzamidine, acetate, FAB 514; [(methyl- [methyl- (4-isopropylbenzenesulfonyl) amino] ethyliamino) methyl] -2-oxooxazolidin-3yl~benzamidine, acetate, FAB 488; [(methyl-{2- [methyl- (4-propylbenzenesulfonyl)aminolethyliamino)methyl] -2-oxooxazolidin-3yllbenzamidine, acetate, FAB 488; [(methyl-{2- [methyl- (4-acetamidobenzenesulfonyl) amino] ethyl} amino) methyl] -2-oxooxazolidin-3yllbenzamidine, trifluoroacetate, FAB 503; [(methyl-{2- [methyl- C2-naphthylsulfonyl) amino] ethyl~amino) methyl] -2-oxooxazolidin-3-yl}benzamidine, acetate, FAB 496; [(methyl-{2- [methyl- (3-trifluoromethylbenzenesulfonyl) amino] ethyl~amino) methyl] -2oxooxazolidin-3-yllbenzamidine, trifluoroacetate, FAB 514; 4-{5-[(methyl-{2-[methyl-(3-amino-4chlorobenzenesulfonyl) amino] ethyl) amino) methyl] -2oxooxazolidin-3-yl~benzamidine, acetate, FAB 495; 69 (methyl-{2- [methyl (phenylethylsulfoiyl) amino] ethyliamino) methyl] -2-oxooxazolidin-3-yl)benzamidine, trifluoroacetate, FAB 474; (methyl-{2- [methyl (benzylsulfonyl) amino] ethyl~amino) methyl] -2-oxooxazolidin-3-yl~benzamidine, trifluoroacetate, FAB 460; 4-{5-[(methyl-{2- [methyl- (4-tolylsulfonyljamino]ethyl~amino) methyl] -2-oxooxazolidin-3-yl~benzamidine, acetate, FAB 460; 4 (methyl [methyl (4 -methoxybenzene sulfonyl)aminolethyl~anino)methyl] -2-oxooxazolidin-3yl~benzamidine, trifluoroacetate, FAB 476; 4 (methyl [methyl (i -naphthyl sul fonyl) amino] ethyl~amino) methyl] -2-oxooxazolidin-3-yl}benzamidine, trifluoroacetate, FAB 496; [(methyl-{2- [methyl- (4-biphenylylsulfonyl) aminolethyl~amino)methyl] -2-oxooxazolidin-3-yl}benzamidine, trifluoroacetate, FAB 522; [(methyl-{2- [methyl- (3,4difluorobenzenesulfonyl) amino] ethyl~amino) methyl] -2oxooxazolidin-3-yl~benzamidine, trifluoroacetate, FAB 516; 4 (methyl-{(2 [methyl (4 -pentylbenzene sulfonyl)amino] ethyliarnino) methyl] -2-oxooxazolidin-3yl~benzamidine, trifluoroacetate, FAB 516; 4-{5-[(methyl-{2-[methyl-(4butylbenzenesulfonyl) amino] ethyliamino) methyl] -2oxooxazol idiri-3-yl }benzamidine, trifluoroacetate, FAR 502; 70 [(methyl-{2- [methyl- (4-methylsulfonylbenzenesulfonyl) amino] ethyl~amino)methyl] -2oxooxazol idin- 3-yl }benzamidine, trifluoroacetate, FAB 502; [(methyl-{2- [methyl- (6-chloro-2-naphthyl sulfonyl) amino] ethyliamino) methyl] -2-oxooxazolidin-3yllbenzamidine, trifluoroacetate, FAB 530.
Similarly to Examples 3 and 4, 6-chloro-N-methyl-N- (methyl-{3- (5-methyl- oxadiazol-3-yl)phenyl] amino) ethyl] -2-naphthylsulfonamide gives the compound [(6-chloro-2-naphthylsulfonyl)methylamino] ethyl }methylamino) -2 -hydroxypropylamino] benzamidine, acetate, FAB 504 HN 1 H N OH and 7-methoxy-N-methyl-N- (methyl-{3- [l,2,4]-oxadiazol-3-yl)phenyl]-2-oxooxazolidin-5-ylmethyliamino) ethyl] -2-naphthylsulfonamide gives the compound 4- [(7-methoxy-2-naphthylsulfonyl)methylamino] ethylimethylamino) -2-hydroxypropylamino] benzamidine, acetate, FAB 500.
Similar to Example 3, cleavage of the oxazolidinone ring of [(methyl-{2- [methyl- (4-biphenylylsulfonyl)amino] ethyl~amino)methyl] -2-oxooxazolidin-3-yl~benzamidine, 71 4-{5-[(methyl-{2-[methyl-(4-isopropylbenzenesulfonyl)amino]ethyl~amino)methyl]-2-oxooxazolidin-3-yl}benzamidine, [(methyl-{2- [methyl- (l-naphthylsulfonyl)amino] ethyl~amino)methyl]- 2 -oxooxazolidin-3-yllbenzamidine, give the compounds below 4-[3-((2-[(4-biphenylylsulfonyl)methylamino]ethyl}methylamino)-2-hydroxypropylamino]benzamidine, diacetate, El 460 -NH 2 4- [(4-isopropylbenzenesulfonyl)methylamino]ethyl~methylamino)-2-hydroxypropylamino]benzamidine, diacetate, El 461; 4-[3-({2-[(l-naphthylsulfonyl)methylaminolethyl}methylamino) -2-hydroxypropylamino benzamidine, diacetate, El 469.
Example 7 A solution of 10.6 g of methyl {3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl]-2-oxooxazolidin-5-yllmethanesulfonate and 3.17 g of sodium azide in 50 ml of acetonitrile is heated under reflux for 40 hours.
Customary work-up gives 5-azidomethyl-3- [1,2,4-oxadiazol-3-yl)phenyl oxazolidin- -one.
7.7 g of azido compound are suspended in ethylene glycol dimethyl ether, 3.6 ml of trimethyl phosphite are then added and the mixture is stirred under reflux for 1.5 hours. 4.9 ml of half-concentrated HCl are added and the mixture is boiled for a further 3 hours.
Customary work-up gives 5-aminomethyl-3- [1,2,4]-oxadiazol-3-yl)phenyl]oxazolidin-2-one hydrochloride.
72 The compound is suspended in dichioromethane, admixed with basic ion exchanger and stirred for 2 hours.
Removal of the ion exchanger and the solvent gives aminomethyl-3- (5-methyl- -oxadiazol-3-yl) phenylloxazolidin-2-one Similarly to Example 1, reaction of "D" with 3,4-difluorobenzenesulfonyl chloride gives 3,4-difluoro-N-{3-[4-(5-methyl-[1,2,4]-oxadiazol- 3-yl)phenyl] sulfonamide; with 4-methoxybenzenesulfonyl chloride gives 4-methoxy-N-{3-[4-(5-methyl-[1,2,4]-oxadiazol.3yl) phenyl] amide; with 4-chloro-3-nitrobenzenesulfonyl chloride gives 4-chloro-3-nitro-N-{3- (5-methyl- oxadiazol-3-yl)phenyl] benzenesulfonamide; with butylsulfonyl chloride gives N-{3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]2- Ibutylsulfonamide; with 3 -trifluoromethylbenzenesulfonyl chloride gives 3 r urmty N 5-ehl-[1 ,4 oxadiazol-3-yl)phenyl] benzenesulfonamide; with 2-naphthylsulfonyl chloride gives N-{f3 -methyl[ 1, 2, 4]-oxadiazol 3 yl) phenyl 12 oxooxazolidin-5-ylmethyl} -2-naphthylsulfonamide.
Similarly to Example 2, the compounds below are obtained by hydrogenation of the sulfonamides -73 [(3,4-difluorobenzenesulforlylamino)methyl] -2oxooxazolidin-3-yllbenzamidine, acetate, FAB 411; 4- [4-methoxybenzenesulfonylamino) methyl] -2oxooxazolidin-3-yllbenzamidine, acetate, FAD 405; [(3-amino-4-chlorobenzenesulfonylamino) methyl] -2-oxooxazolidin-3-yl~benzamidine, acetate, FAD 424; [(butylsulfonylamino)methyl] -2-oxooxazolidin- 3-yl~benzamidine, acetate, FAD 355; [(3-trifluoromethylbenzenesulfonylamino) methyl] -2-oxooxazolidin-3-yl~benzamidine, acetate, FAD 443; [(2-naphthylsulfonylamino)methyl] -2oxooxazolidin-3-yl~benzamidine, acetate, FAD 425.
Example 8 Similarly to Examples 3 and 4, 3,4-difluoro-N-{3-[4-(5-methyl-[,2,4-oxadiazol3yl)phenyl] gives 4- (3,4-difluorobenzenesulfonylamino) -2hydroxypropylaminolbenzamidine, acetate, FAD 385 0 N 11 N/"T N-S 0 4-methoxy-N-{3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl] 2 gives 74 4- (4-methoxybenzenesulfonylamino) -2-hydroxypropylamino] benzamidine; 4-chloro-3-nitro-N-{3-[4-(5-methyl-[l,2,4]-oxadiazol-3yl) phenyl] sulfonamide gives 4- (3-amino-4-chlorobenzenesulfonylanino) -2hydroxypropyl amino] benzamidine; N-{3-[4-(5-methyl-[l,2,4]-oxadiazol-3-yl)phenyl]-2-oxo- }butylsulfonamide gives 4- (butylsulfonylamino) -2 -hydroxypropylamino] benzamidine, acetate, FAB 329; 3-trifluororethyl-N-{3-[4-(5-methyl-[l,2,4]-oxadiazol- 3-yl)phenyl] sulfonamide gives 4- (3-trifluoromethylbenzenesulfonylamino) -2hydroxypropylaminolbenzamidine, acetate, FAB 417; (5-methyl- -oxadiazol-3-yl)phenyl] -2-oxo- 1-2 -propylsulfonamide gives 4- (propylsulfonylamino) -2-hydroxypropylamino] benzamidine, acetate, FAB 391.
Example 9 A solution of 3 0. 0 g of methyl (3 -methyl 4] oxadiazol-3-yl)phenyl] sulfonate and 300 ml of aqueous methylamine solution in 300 ml of THE is heated under pressure at 80 0 C for 18 hours. Customary work-up gives 5-methylaminomethyl-3- (5-methyl- -oxadiazol-3-yl)phenylloxazolidin- 2-one ("Ell).
Similarly to Example 1, reaction of "Ell with butylsulfonyl chloride gives N-methyl-N-{3- (5-methyl- -oxadiazol-3yl)phenyl] with 4-isopropylbenzenesulfonyl chloride gives 4-isopropyl-N-methyl-N-{3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl] benzenesulfonamide; with 3 -trifluoromethylbenzenesulfonyl chloride gives 3-trifluoromethyl-N-methyl-N-{3- -oxadiazol-3-yl)phenyl] methyl }benzenesulfonamide; with phenylvinylsulfoiyl chloride gives N-methyl-N-{3-[4-(5-methyl-[1,2,4]-oxadiazol-3yl) phenyl] sulfonamide; with 2-naphthylsulfonyl chloride gives N-methyl-N-{3-[4-(5-methyl-[1,2,4]-oxadiazol-3yl)phenyl] -2-oxooxazolidin-5-ylmethyl}-2-naphthylsulfonamide; with 4-propylbenzenesulfonyl chloride gives 4-propyl-N-methyl-N-{3-[4-(5-methyl-[l,2,4]oxadiazol-3-yl)phenyl] benzenesul fonamide; with 4-methoxybenzenesulfonyl chloride gives 4-methoxy-N-methyl-N-{3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyll benzenesulfonamide; with 2,4, 6-trimethylbenzenesulfonyl chloride gives 2,4,6-trirnethyl-N-methyl-N-{3- [1,2,4]-oxadiazol-3-yl)phenyl]-2-oxooxazolidin-5ylmethyl }benzenesulfonamide; with benzoyl chloride gives 76 N-methyl-N-{3-[4-(5-methyl-[l,2,4]-oxadiazol-3 yl)pheiyl] 2 with 2-riaphthylcarbonyl chloride gives N-methyl-N-{3-[4-(5-methyl-[l,2,4]-oxadiazop3yl)phenyl] -2-oxooxazolidirl-5-ylmethyl}-2-naphthylcarboxamide; with cyclohexylcarbonyl chloride gives N-methyl-N-{3-[4-(5-methyl-[1,2,4]-oxadiazol-3 yl)phenyl] carboxamide; with 4-biphenylylcarboiyl chloride gives N-methyl-N-{3-[4-(5-methyl-[l,2,43-oxadiazol-3 yl)pheiyl] -2-oxooxazolidin-5-ylmethyl}-4-biphenylylcarboxamide; with 4-chlorobenzoyl chloride gives 4-chloro-N-methyl-N-{3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl] benzamide; with 4- 1-dimethylpropyl)benzenesulfonyl chloride gives 4- (1,l-dimethylpropyl) -N-methyl-N-{3- [1,2,4]-oxadiazol-3-yl)pheriyl]-2-oxooxazolidin-5ylmethyl }berzeresulforiamide; with 3,4-difluorobenzenesulfonyl chloride gives 3,4-difluoro-N-methyl-N-{3- (5-methyl- oxadiazol-3-yl)pheiyl] benzenesulfonamide; with 4-tert-butylbenzenesulfonyl chloride gives 4-tert-butyl-N-methyl-N-{3-[4-(5-methy[l,2,4I oxadiazol--3-yl)phenyl] benzeriesulfonamide; 77 with 4 -trifluoromethylbenzenesulfonyl chloride gives 4-trifluoromethyl-N-methyl-N-{3- -oxadiazol-3-yl)phenyl] ylmethyl }benzenesulfonamide; with 4-pentylbenzenesulfonyl chloride gives 4-pentyl-N-methyl-N-{3- (5-methyl- oxadiazol-3-yl)pheiyl] benzenesul fonamide; with l-naphthylsulfonyl chloride gives N-methyl-N-{3- (5-methyl- -oxadiazol-3yl)phenyl] naphthylsulfonamide.
Similarly to Example 2, the compounds below are obtained [((butylsulfonyl)methylamino) methyl] -2oxooxazolidin-3-yllbenzamidine, acetate, FAB 369 0 [((4-isopropylbenzenesulfonyl)methylamino) methyl] -2-oxooxazolidin-3-yl~benzamidine, acetate, FAB 431; [((3-trifluoromethylbenzenesulfonyl)methylamino) methyl] 2 -oxooxazolidin-3-yl~benzamidine, acetate, FAB 457; [((phenylethylsulfonyl)methylamino) methyl] -2oxooxazolidin-3-yl~benzamidine, acetate, FAR 417; [((2-naphthylsulfonyl)methylamino)methyl] -2oxooxazol idin- 3-yllIbenzamidine; 78 -propylbenzenesul fonyl) methylamino) methyl] -2-oxooxazolidin-3-yl }benzamidine; -methoxybenzenesul fonyl) methyl amino) methyl] -2-oxooxazolidin-3-yl~benzamidine; 4, 6 -trime thyl benzene sul fonyl) methyl amino) methyl] -2-oxooxazolidin-3-yl~benzamidine; [(benzoylmethylamino) methyl] -2-oxooxazolidin- 3-yl }benzamidiie; [(2-naphthylcarbonylmethylamino) methyl] -2oxooxazolidin-3-yl }benzamidine; [(cyclohexylcarboriylmethylamino)methyl] -2oxooxazolidin-3-yl }benzamidine; [(4-biphenylylcarbonylmethylamino) methyl] -2oxooxazolidin-3 -yl }benzamidine; [(4-chlorobenzoylmethylamino) methyl] -2-oxooxazolidin-3-yllbenzamidine.
Similarly, methyl {3-[4-(5-methyl-[1,2,4]-oxadiazol-3yl)phenyl] -2-oxooxazolidin-5-yl~methanesulfonate and butylamine give the compound 5-butylaminomethyl-3- [4- -oxadiazol-3-yl)phenylloxazolidin-2one Reaction of "IE-1" with 6-chloro-2-naphthylsulfonyl chloride gives 6-chloro-N-butyl-N-{3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl] -2-oxooxazolidin-5-ylmethyl}-2naphthyl sulfonamide; with 4-biphenylylsulfonyl chloride gives 79 N-butyl-N-{3- (5-methyl- -oxadiazol-3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl)-4-biphenylylN sulfonamide; with 2-naphthylsulfonyl chloride gives N-butyl-N-{3- (5-methyl- -oxadiazol--3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl}-2-naphthylsulfonamide.
Example Similarly to Examples 3 and 4, N-methyl-N-{3- (5-methyl- -oxadiazol-3-yl) phenyl] gives [(butane-l-sulfonyl)methylamino] -2-hydroxypropylamino }benzamidine 0 H2NO 4-isopropyl-N-methyl-N-{3- [4-(5-methyl- [l,2,4]-oxadiazol-3-yl)phenyl] sulfonamide gives [(4-isopropylbenzenesulfonyl) methylamino] -2hydroxypropylamino~benzamidine, acetate, FAB 405; 3-trifluoromethyl-N-methyl-N-{3- [4-(5-methyl- oxadiazol-3-yl)phenyl] benzenesul fonamide gives [(3-trifluoromethylbenzenesulfonyl)methylamino] -2-hydroxypropylaminolbenzamidine, acetate, FAB 431; N-methyl-N-{3- (5-methyl- -oxadiazol-3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl }phenylvinylsulfonamide gives [(phenylethylsulfonyl)methylamino] -2hydroxypropylaminolbenzamidine; N-methyl-N-{3- (5-methyl- -oxadiazol-3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl }-2-naphthylsulf onamide gives [(2-naphthylsulfonyl)methylamino] -2-hydroxypropylaminolbenzamidine, acetate, FAR 413; 6-chloro-N-methyl-N-{3- [4-(5-methyl-[1,2,4]-oxadiazol- 3-yl)phenyl] -2-oxooxazolidin-5-ylmethyl}-2-naphthy..
sulfonamide gives [(6-chloro-2-naphthylsultonyl)methylamino -2hydroxypropylamino~benzamidine, acetate, FAB 447; 4-propyl-N-methyl-N-{3- (5-methyl- -oxadiazol- 3-y1) phenyl] sulfonamide gives [(4-propylbenzenesulfonyl) methylamino] -2hydroxypropylaminolbenzamidine, acetate, FAB 405; 4-methoxy-N-methyl-N-{3- (5-methyl- -oxadiazol- 3-yl)phenyl] amide gives [(4-methoxybenzenesulfonyl)methylamino] -2hydroxypropylamino~benzamidine, acetate, FAB 393; 2,4,6-trimethyl-N-methyl-N-3-[4-(5-methya124] oxadiazol-3-yl)phenyl] benzenesulfonamide gives [(2,4,6-trimethylbenzenesulfonyl)methylamino] -2-hydroxypropylamino~benzamidine, acetate, FAR 405; [(benzoylmethylamino) methyl] -2-oxooxazolidin-3yl }benzamidine gives [(benzoylmethylamino] -2-hydroxypropylamino} benzamidine; [(2-naphthylcarbonylmethylamino) methyl] -2-oxooxazolidin-3-yl~benzamidine gives 81 4-f{3- naphthyl carbonylme thyl amino] -2-hydroxypropylamino }benzamidine; (cycl1ohexyl carbonylme thyl amino) methyl] -2-oxooxazolidin-3-yl }benzamidine gives 4 f{3- (cyc lohexyl carbonylme thyl amino] -2 -hydroxypropylaminolbenzamidine; (4 -biphenylylcarbonylmethyl aminio)methyl]I -2-oxooxazolidin-3 -yl }benzamidine gives 4 -1 (4 -biphenylyl carbonylmethyl aminoj -2-hydroxypropylamino~benzamidine; (4 -chlorobenzoylmethyl aminio) methyl]I -2-oxooxazolidin-3-yl }benzamidine gives 4 (4 -chlorobenzoylrnethyl amino] 2-hydroxypropylaminolbenzamidine; 4- 1-dimethyipropyl) -N-methyl-N-{3-[f4- 1, 2, 4 -oxadiazol 3-yl) phenyl]1-2 -oxooxazol idin- 5-yl methyl }benzenesulfonamide gives 4 (4 1 -dime thylpropyl) benzenesul fonyl) methylamino] 2 -hydroxypropyl amino) benzami dine, acetate, FAB 433; 3,4-difluoro-N-methyl-N-3- [4-5-methyl- [1241oxadiazol-3-yl)phenyl] 2 sulfonamide gives (3-f luoro-4-methoxybenzenesulfonyl)methylamino] -2-hydroxypropylaminolbenzamidine, acetate, FAB 411; 4-tert-butyl-N-methyl-N-{(3- (5-methyl- -oxadiazol-3-yl)phenyl] sulfonamide gives [(4-tert-butylbenzenesulfonyl)methylamino] -2hydroxypropylamino~benzamidine, acetate, FAB 419; 4-trifluoromethyl-N-methyl-N.{(3- (5-methyl- oxadiazol--3-yl)phenyl] 2' benzenesulfonamide gives 82 (4-trifluoromethylbenzenesulfonyl)methylamino] -2-hydroxypropylamino~benzamidine, acetate, FAB 431; 4-pentyl-N-methyl-N-{3- (5-methyl- -oxadiazol- 3-yl)phenyl] amide gives 4-f{3- (4-pentylbenzenesulfonyl) methylamino] -2hydroxypropylamino~benzamidine, acetate, FAB 433; N-methyl-N-{3- (5-methyl- -oxadiazol-3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl} -l-naphthylsulf onamide gives [(1-naphthylsulfonyl)methylamino] -2-hydroxypropylamino~benzamidine, acetate, FAB 413; 6-chloro-N-butyl-N-{3-[4-(5-methyl- [1,2,4]-oxadiazol-3yl)phenyl] -2-oxooxazolidin-5-ylmethyl)-2-naphthylsulfonamide gives 4-13- (6-chloro-2-naphthylsulfonyl)butylamino] -2hydroxypropylamino }benzamidine; N-butyl-N-{3- (5-methyl- -oxadiazol-3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl} -4-biphenylylsulfonamide gives (4-biphenylylsulfonyl) butylamino] -2hydroxypropylaminol}benzamidine; N-butyl-N-{3- (5-methyl- 2,4] -oxadiazol-3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl} -2-naphthylsulfonamide gives (2-naphthylsulfonyl)butylamino] -2-hydroxypropylaminolbenzamidine.
N-methyl-N-{f3- (5-methyl- -oxadiazol-3-yl) phenyl] -2-oxooxazolidin-5-ylmethyl}- (7-methoxy- 2-naphthyl) sulfonamide gives 83 7 -methoxy-2-naphthylsulfonyl)methylaminoI 2 -hydroxypropyl amino Ibenz ami dine, acetate, FAB 443; N-methyl-N-{3- (5-methyl- -oxadiazol-3-y1) phenyl] -2-oxooxazolidin-5-ylmethyl}- (6-methoxy- 2-naphthyl) sulfonamide gives 4 (6 -methoxy- 2-naphthylsul fonyl) methylamino] 2 -hydroxypropyl amino) benzamidine, acetate, FAB 443.
Example 11 A solution of 10.9 g of 3 methyloxazolidin-2 -one 5.9 g of 3-cyanophenol, 26.2 g of triphenyiphosphine and 13.1 g of diethyl azodicarboxylate in 250 ml of THF is stirred under an atmosphere of protective gas for 4 hours. Customary work-up gives 3 (4 -cyanophenyl) 5- (3 -cyanophenoxy) methyl] oxazolidin-2-one.
A solution of 8.5 g of the dicyano, compound, 5.5 g of hydroxylammonium chloride and 11.2 g of sodium carbonate in 130 ml of DMF is stirred at 60 0 C for 3 hours. Customary work-up gives 3-(4-N-hydroxyamidinophenyl) 5- (3 -N-hydroxyamidinophenoxy) methyl]I oxazolidin-2 -one.
Similarly to Example 2, by hydrogenation, this gives the compound 3 (4 -amidinophenyl) 5- (3 amidinophenoxy) methyl Ioxazolidin2 -ne, diacetate, m.p.
159-160 0 C, FAB 354.
Similarly, reaction of "IF" with 4'-hydroxybiphenyl-4-carbonitrile, reaction with hydroxylammonium chloride and reduction gives the compound 3- (4-amidinophenyl) -amidino-4-biphenylyl- .~oxy)methylloxazolidin-2-one, diacetate, m.p. 214-224WC; 84 with 4-cyanophenol, reaction with hydroxylammonium chloride and reduction gives the compound 3- (4-amidinophenyl) [(4-aridinophenoxy) methyl] oxazolidin-2-one, diacetate, m.p. 1640C (decomposition); with 4 -cyano -N (et hoxycarbonyl) benzene sul fonami de gives the compound N- (4-cyanophenyl) -2-oxooxazolidin-5-ylmethyl] N-ethoxycarbonyl-4 -cyanobenzenesulfonamide, diacetate, FAB 489.
Example 12 A solution of 400 mg of methyl {3-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl] sulfonate, 240 mg of phenylpiperazine and 120 mg of sodium bicarbonate in 10 ml of acetonitrile is heated at 80 0 C for 18 hours. Customary work-up gives methyl- -oxadiazol-3-yl)phenyll (4-phenylpiperazin-1-ylmethyl) oxazolidin-2-one.
By hydrogenation similarly to Example 2, this gives 4- [2-oxo-5- (4-phenylpiperazin-l-ylmethyl)oxazolidin-3-yl]benzamidine, acetate, FAB 380.
Similarly, the reaction of with 1,3] -thiadiazole gives the compound 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyll-5- (benzo- methyl] oxazolidin-2-one.
By hydrogenation similarly to Example 2, this gives 4-{2-oxo-5-[4-(benzo-[2,l,3]-thiadiazol-5-ylmethyl)piperazin-l-ylmethylloxazolidin-3-yl~benzamidine, aceae FAB 512.
Similarly, reaction of methyl (5-methyl- oxadiazol-3-yl)phenyl] 2 sul fonate with 2-piperazin-1-ylpyrimidine gives 3- (5-methyl- -oxadiazol-3-yl)pheiyl] (pyrimidin-2-yl)piperazin-1-ylmethylloxazolidin-2 one, with benzylpiperazine gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] [4-benzylpiperazin-l-ylmethyl] oxazolidin-2-one, with (benzo- -thiadiazol-5-yl)piperazine gives 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]-5- (benzo- methyl] oxazolidin-2-one.
Similarly to Examples 3 and 4, the cleavage of the oxazolidinone ring and the oxadiazole ring of 3-[4-(5-methyl-[l,2,4]-oxadiazol-3-yl)phenyl]-5-[4- (pyrimidin-2-yl) piperazin-1-ylmethyl] oxazolidin-2-one gives 4- [2-hydroxy-3- (4-pyrimidin-2-ylpiperazin-l-yl) propylaminolbenzamidine, acetate, FAB 356; of 3-[4-(5-methyl-[l,2,4]-oxadiazol-3-yl)phenyl]-5-[4benzylpiperazin-l-ylmethyll oxazolidin-2-one gives 4- [2-hydroxy-3- (4-benzylpiperazin-l-yl)propylamiriolbenzamidine, acetate, FAB 368; of 3-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]-5-[4- (benzo- -thiadiazol-5-yl)piperazin-1-ylmethyl] oxazolidin-2-one gives 4- [2-hydroxy-3- (benzo- -thiadiazol-5-yl) piperazin- 1-yl)propylaminolibenzamidine, trifluoroacetate, FAB 412.
86 4- (5-methyl- -oxadiazol-3-yl)phenyl] [4- 5-dimethoxybenzyl)piperazin-1-ylmethyl] oxazolidin- 2-one gives 4-{2-hydroxy-3- l-yllpropylaminolbenzamidine, FAB 428.
Similarly, reaction of methyl {3-[3-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl] sulfonate with 4-piperazin-l-ylpyridine gives 3-[3-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyll-5- (pyridin-4-yl)piperazin-l-ylmethyl]oxazolidin-2-one which is converted by hydrogenation into 3-{2-oxo-5- (pyridin-4-yl)piperazin-1-ylmethyl] oxazolidin-3-yllbenzamidine, acetate, FAB 381, m.p.
152-165 (decomp.).
Example 13 A solution of 200 mg of and 66 mg of butyl isocyanate in 10 ml of dichloromethane is stirred for 4 hours. 400 mg of aminomethylpolystyrene are added, and the mixture is stirred for a further 12 hours. The polystyrene and solvent are removed, giving, after customary work-up, 3- (5-methyl- -oxadiazol-3yl)phenyl] (4-butylaminocarbonylpiperazin-l-ylmethyl) oxazolidin-2-one.
Similarly, reaction of "All with cyclohexyl isocyanate gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (cyclohexylaminocarbonyl)piperazin-1-ylmethyl] oxazolidin-2 -one; with 4-methoxyphenyl isocyanate gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-methoxyphenyl) aminocarbonyl] piperazin-1-ylmethyl }oxazolidin-2-one; -87 with 4-trifluoromethyiphenyl isocyanate gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-trifluoromethyiphenyl) aminocarbonyllpiperazinl-ylmethyl }oxazolidin-2-one; with 4-chiorophenyl isocyanate gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4-chiorophenyl) aminocarbonyl] piperazin-1-ylmethyl }oxazolidin-2-one; with 3-ethoxycarbonyiphenyl isocyanate gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (3-ethoxycarbonyiphenyl) aminocarbonyllpiperazinl-ylmethyl }oxazolidin-2 -one; with l-naphthyl isocyanate gives 3- (5-methyl- -oxadiazol-3-yl)phenyl] (naphth-l-ylaminocarbonyl)piperazin-1-ylmethyl] oxazolidin-2 -one.
By hydrogenation similarly to Example 2, 3- (5-methyl- -oxadiazol-3-yl)phenyl]
[N-
(4 -methoxyphenyl) aminocarbonyl] piperazin- 1-ylmethyl oxazolidin-2-one gives 4-{2-oxo-5-{4- (4-methoxyphenyl)aminocarbonyl] piperazin-l-ylmethyl~oxazolidin-3-yl }benzamidine, acetate, FAB 453 HN 0 0 3- (5-methyl- -oxadiazol-3-yl)phenyl]
[N-
(4 -trifluoromethylphenyl) aminocarbonyllpiperazin-i-ylmethyl~oxazolidin-2-one gives 88 4-{2-oxo-5-{4- (4-trifluoromethylphenyl)aminocarbonyllpiperazin-1-ylmethyl~oxazolidin-3-yl~benzamidine, acetate, FAB 473; 3-[4-(5-methyl-[l,2,4]-oxadiazol-3-yl)phenyl]--14-[N- (4-chlorophenyl) arinocarborylpiperazin-l-ylmethyl} oxazolidin-2-one gives 4-{2-oxo-5-{4-[N-(4-chlorophenyl)aminocarbonyl]piperazin-1-ylmethyl }oxazolidin-3-yl~benzamidine, acetate, FAB 457; 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4butylaminocarboriylpiperazin-1-ylmethyl) oxazolidin-2-one gives 4- [2-oxo-5- (4-butylaminocarbonylpiperazin-1-ylmethyl)oxazolidin-3-yllbenzamidine, acetate, FAB 403; 3- (5-methyl- -oxadiazol-3-yl)phenyl]
[N-
(3-ethoxycarbonyiphenyl) aminocarbonyllpiperazin-l-ylmethyl~oxazolidin-2-one gives 4-{2-oxo-5-{4- (3-ethoxycarbonylphenyl)aminocarbonyl] piperazin- 1-ylmethyl loxazolidin- 3-yl }benzamidine, acetate, FAB 495; 3 -[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenylps.-[4.
(naphth-l-ylaminocarbonyl)piperazin-1-ylmethyl] oxazolidin-2-one gives 4-{2-oxo-5- (raphth-1-ylaminocarbonyl)piperazin- 1-ylmethylloxazolidin-3-yl~benzamidine, acetate, FAB 403.
Similarly to Examples 3 and 4, 3- (5-methyl- -oxadiazol-3-yl)phenyl] (4butylaminocarbonylpiperazin-l-ylmethyl) oxazolidin-2-one gives 4- (4-butylaminocarbonylpiperazin-1lyl) -2hydroxypropylaminolbenzamidine, acetate, FAB 377; -89 3- (5-methyl- -oxadiazol-3-yl)phenyl] [4- (cyclohexylaminocarbonyl) piperazin- 1-ylmethyl] oxazolidin-2-one gives 4- (4-cyclohexylaminocarbonylpiperazin-1-y1)-2hydroxypropylaminolbenzamidine, acetate, FAB 403
H\
4 yHNY N 0<N H H OH O 4N:
H
Example 14 A solution of 1 equivalent of methyl {3-[4-(5-methyl- -oxadiazol-3-yl)phenyl] methanesulfonate, 3 equivalents of glycine benzyl ester, methane sul fonate, and 3 equivalents of sodium bicarbonate in acetonitrile is heated under ref lux for 18 hours. Customary work-up gives benzyl{{3-[4-(5methyl- -oxadiazol-3-yl)phenyl] -2-oxooxazolidin- Similarly to Example 1, reaction of "G"I with 6-chloronaphth-2-ylsulfonyl chloride gives benzyl [6-chloronaphth-2-ylsulfonyl] [4- [l,2,4]-oxadiazol-3-yl)phenyl]-2-oxooxazolidin-5-ylmethyl~amino} acetate.
By hydrogenation similarly to Example 2, this gives [6-chloronaphth-2-ylsulfonyll (4-amidinophenyl) -2-oxooxazolidin-5-ylmethyl] amino~acetic acid, acetate, FAB 517, and benzyl [6-chloronaphth-2-ylsulfonyl] (4amidinophenyl) 2 -oxooxazolidin-5-ylmethyl] amino} acetate.
Similarly, reaction of "G" 90 with naphth-2-ylsulfonyl chloride and subsequent hydrogenation gives [naphth-2-ylsulfonyl] (4-amidinophenyl) -2aminolacetic acid, acetate, FAB 483 0 N x with 4-methoxybenzenesulfonyl. chloride and subsequent hydrogenation gives [4-methoxybenzenesulfonyl] (4-amidinophenyl) -2-oxooxazolidin-5-ylmethyllamino~acetic acid, acetate, FAB 453; with phenylvinylsulfonyl chloride and subsequent hydrogenation gives benzyl [phenylvinylsulfonyl] (4-aminophenyl) -2-oxooxazolidin-5-ylmethyl] aminolacetate, acetate, FAB 549; with 4-biphenylylsulfonyl chloride and subsequent hydrogenation gives [4-biphenylylsulfonyl] (4-amidinophenyl) 2 -oxooxazolidin-5-ylrnethyll amino) acetic acid, acetate, FAB 509; with 4-propylbenzenesulfonyl chloride and subsequent hydrogenation gives benzyl [4-propylbenzenesulfonyl] (4amidinophenyl) ylmethyllaminolacetate, acetate, FAB 565.
91 Example A solution of 4-oxiranylmethoxybenzonitrile and BOCpiperazine in methanol is stirred under ref lux for 4 hours. Customary work-up gives 4- [2-hydroxy-3- (4-BOCpiperazin-l-yl)propoxy] benzonitrile. The subsequent reaction with hydroxylarnine hydrochloride affords Nhydroxy-4- [2-hydroxy-3- (4-BOC-piperazin-l-yl)propoxy] benzamidine. Subsequent acylation with acetic anhydride gives 2-acetoxy-l- (4-BOC-piperazin-l-yl) methyl- -oxadiazol-3-yl)phenoxylpropane. After removal of the BOC group with HC1 in dioxane, reaction with 4-propylphenylsulfonyl chloride gives the compound 2-acetoxy-l- (4-propylphenylsulfonyl)piperazin-1-yl] 3- (5-methyl- [l,2,4]-oxadiazol-3-yl)phenoxylpropane.
Reaction similarly to Examples 3 and 4 gives the compound 4 -{(2-hydroxy- 3- [4 (4 -propyiphenylsul fonyl) piperazin-1-yl] propoxylbenzamidine
HNN
OH N-S
I
3-{2-hydroxy-3- (4-biphenylylcarbonyl)piperazinl-ylllpropoxy~benzamidine, acetate, FAB 459; 3-{2-hydroxy-3- (6-chloro-2-naphthylsulfonyl)piperazin-1-yllpropoxy~benzamidine, acetate, FAB 503; 3-{2-hydroxy-3- (2-naphthylsulfonyl)piperazin-lyl] propoxy~benzamidine, acetate, FAB 469; 3-{2-hydroxy-3- (4-propyiphenylsulfonyl) piperazin-1-yllpropoxylbenzamidine, acetate, FAB 461; LI 92 3 -{(2-hydroxy- 3- [4 (4 -isopropylphenylsul fonyl) piperaz in-l1-yl Ipropoxy Ibenzami dine, acetate, FAD 461; 3-{2-hydroxy-3- (4-methoxyphenylsulfonyl) piperazin-1-yllpropoxylbeizamidine, acetate, FAD 449; 3-{2-hydroxy-3- (4-butyiphenylsulfonyl) piperazin-1-yllpropoxylbenzamidiie, acetate,' FAB 399; 3-{2-hydroxy-3- [4-benzoylpiperazin-1-yllpropoxy}benzamidine, acetate, FAB 383; 3-{2-hydroxy-3- (7-rethoxy-2-naphthylsulfonyl) piperazin-l-yllpropoxylbenzamidine, acetate, FAD 499; 3 -{(2-hydroxy- 3- [4 (3,5S-dirnethoxybenzyl) piperazinl-yillpropoxy~benzamidine, acetate, FAB 429; 3-{2-hydroxy-3- (4-biphenylylsulfonyl)piperazinl-yllpropoxy~benzamidine, diacetate, FAB 495; 3-{2-hydroxy-3- (naphth-2-ylmethyl)piperazin-lyl]I propoxy) benzami dine, diacetate, FAB 419; 3 -{(2-hydroxy- 3- [4 (2 -naphthylcarbonyl) piperazinl-yllpropoxylbenzamidine, diacetate, FAB 433; 3 -{(2-hydroxy- 3- [4 (4 -biphenyl -4 -ylmethyl) piperaz in-l1-yl Ipropoxy) benzami dine, diacetate, FAB 445.
Example 16 10.0 g of 3-oxiranylmethoxybenzonitrile and 7.1 g of 3-cyanophenol together with 173 mg of caesium fluoride are molten at 130 0 C. Customary work-up gives 11.8 g of 1, 3-bis- (3-cyanophenoxy) -2-hydroxypropane.
Subsequent reaction with hydroxylammonium chloride gives 1, 3-bis- (N-hydroxyamidino)phenoxy] -2-hydroxy- 93 propane. Hydrogenation similarly to Example 2 gives 1,3-bis- (3-amidinophenoxy) -2-hydroxypropane, diacetate, FAB 329
H
2 N NH HN NH2
HO
Similarly, the compounds 1, 3-bis- (4-amidinophenoxy) -2-hydroxypropane, diacetate, FAB 329 and 1- (3-amidinophenoxy) (4-amidinophenoxy) 2-hydroxypropane, are obtained.
Similarly, reaction of with the phenols below 4-chlorophenol, 4-methylphenol, phenol, 4-methoxyphenol, 4-cyclohexylphenol and subsequent reaction with hydroxylammonium chloride and hydrogenation gives the compounds below 1- (3-amidinophenoxy) -2-hydroxy-3- (4-chlorophenoxy)propane, 1- (3-amidinophenoxy) -2-hydroxy-3- (4-methylphenoxy)propane, 1- (3-amidinophenoxy) -2-hydroxy-3-phenoxypropane, 1- (3-amidinophenoxy) -2-hydroxy-3- (4-methoxyphenoxy)propane, 94 1- (3-amidinophenoxy) -2-hydroxy-3- (4-cyclohexylphenoxy) propane.
Example 17 A solution of 1 equivalent of N-{3-[4-(5-methyl- [1,2,4]-oxadiazol-3-yl)phenyl]-2-oxooxazolidin-5-yl.
methyl}- (6-chloro-2-naphthyl)sulfonamide
("III)
[obtainable by reaction of 5-aminomethyl-3-[4-(5methyl- -oxadiazol-3-yl)phenyl [oxazolidin-2-one with 6-chloro-2-naphthylsulfonyl chloride], 1.1 equivalents each of N,N'-dimethylchloroacetamide and caesium carbonate in DMF is stirred at room temperature for 12 hours. Customary work-up gives 2-((6-chloro-2naphthylsulfonyl)-{3-[4-(5-methyl-[l,2,4]-oxadiazol-3yl)phenyl] -2-oxooxazolidine-5-ylmethyl~amino) dimethylacetamide.
Similarly to Examples 3 and 4, this gives the compound 2-[[3-(4-amidinophenylanino)-2-hydroxypropyl]- (6chloro-2-naphthylsulfonyl) amino] -dimethylacetamide C1 0 HN N \\e
H
2 N KI 2 OH 0 Similarly, reaction of with N,N' -diethyichioroacetamide, N, N'-dipropylchloroacetamide, N-phenylchloroacetamide, N,N' -diphenylchloroacetamide and ethyl chloroacetate 95 and subsequent cleavage of the oxazolidinone ring and the oxadiazole ring similarly to Examples 3 and 4 gives the compounds 2- (4-amidinophenylamino) -2-hydroxypropyl] (6-chloro-2-naphthylsulfonyl)anino] -diethylacetamide, 2- (4-amidinophenylamino) -2-hydroxypropyl] (6-chloro-2-naphthylsulfonyl)amino] -dipropylacetamide, 2- (4-amidinophenylamino) -2-hydroxypropyl] (6-chloro-2-naphthylsulfonyl) amino] -N-phenylacetamide, 2- (4-amidinophenylamino) -2-hydroxypropyl] (6-chloro-2-naphthylsulfonyl) amino] -dipenylacetamide and 2- (4-amidinophenylamino) -2-hydroxypropyl] (6-chloro-2-naphthylsulfonyl) amino] acetic acid, acetate FAB 491.
Similarly, by reaction of N-{3-E4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl] -2-oxooxazolidin-5-ylmethyl) isopropylphenyl) sulfonamide with N, N'-dimethylchloroacetamide, N,N' -diethylchloroacetamide, N,N' -dipropylchloroacetamide, N-phenylchloroacetamide, N, N'-diphenylchloroacetamide, benzyl bromide, iodobutane, 4-chloromethyl-2-methylthiazole, 4-me thoxybenzyl bromide, ethyl chloroacetate, ethyl 4 -chiorobutyrate, ethyl 3-chloromethylbenzoate, -96 ethyl 4- chloromethylbenzoate, 3, S-dimethoxybenzyl bromide, 4-(5-methyl-[1,2,4]-oxadiazol-3-yl)benzyl bromide, 3- (5-methyl- -oxadiazol-3-yl)benzyl bromide and 2-f luorobenzyl bromide and subsequent cleavage of the oxazolidinone ring and the oxadiazole ring similarly to Examples 3 and 4 gives the compounds 2- (4-amidinophenylamino) -2-hydroxypropyl] (4-isopropylsulfonyl) amino] [-dimethylacetamide, 2- (4-amidinophenylamino) -2-hydroxypropyl] (4-isopropylsulfonyl)amino] -diethylacetamide, 2- (4-amidinophenylanino) -2-hydroxypropyl] (4-isopropylsulfonyl) amino] -dipropylacetamide, 2- (4-amidinophenylamino) -2-hydroxypropyl] (4-isopropylsulfonyl) amino] -N-phenylacetamide, 2- (4-amidinophenylamino) -2-hydroxypropyl] (4-isopropylsulfonyl) amino] -diphenylacetamide, (2-hydroxy) [(4-isopropylbenzenesulfonyl) benzylamino] propylamino~benzamidine, acetate, FAB 481, (2-hydroxy) [(4-isopropylbenzenesulfonyl) butylaminolpropylamino~benzamidine, acetate, FAB 447, (2-hydroxy) [(4-isopropylbenzenesulfonyl) (2-methylthiazol-4-ylmethyl) aminolpropylamino} benzamidine, acetate, FAB 502, (2-hydroxy) [(4-isopropylbenzenesulfonyl) methoxybenzyl) amino] propyl amino }benzamidine, acetate, FAB 511, -97 2- (4-amidinophenylamino) -2-hydroxypropyl] isopropylbenzenesulfonyl) amino] acetic acid, acetate, FAB 449, 4- (4-amidinophenylamino) -2-hydroxypropyl] isopropylbenzenesulfonyl) amino] butyric acid, diacetate, FAB 477, (4-amidinophenylamino) -2-hydroxypropyl] (4-isopropylbenzenesulfonyl) amino] methyl~benzoic acid, diacetate, FAD 525, (4-amidinophenylamino) -2-hydroxypropyl] (4-isopropylbenzenesulfonyl) amino] methyl~benzoic acid, diacetate, FAB 525 o\s HN /-rN H2N H OH
I
OH
0 (2-hydroxy) [(4-isopropylbenzenesulfonyl) 5-dimethoxybenzyl) aminolpropylaminolbenzamidine, diacetate, FAB 541, (2-hydroxy) [(4-isopropylbenzenesulfonyl) (4-amidinobenzyl) amino] propylamino~benzamidine, triacetate, FAD 523, (2-hydroxy) [(4-isopropylbenzenesulfonyl) (3-amidinobenzyl) amino] propylamino~benzamidine, triacetate', FAB-523 and 98 4- {(2-hydroxy) [(4-isopropylbenzenesulfonyl) (2-f luorobenzyl) amino] propylaminolbenzamidine, diacetate, FAB 499.
Similarly, reaction of with iodoethane, benzyl bromide, 4 -methoxybenzyl bromide, 2 -bromomethylnaphthalene, 4-chloromethyl-2-methylthiazole and 4 -methoxybenzyl chloride and subsequent cleavage of the oxazolidinone ring and the oxadiazole ring similarly to Examples 3 and 4 gives the compounds [(6-chloro-2-naphthylsulfonyl)ethylamino] 2 -hydroxypropyl amino }benzamidine
HN
2 OH [(6-chloro-2-naphthylsulfonyl)benzylamino] 2 -hydroxypropylamino~benzanidine, [(6-chloro-2-naphthylsulfonyl) -(4-methoxybenzyl) amino] -2-hydroxypropylamino~benzamidine, [(6-chloro-2-naphthylsulfonyl) -(naphth-2-ylmethyl) amino] -2 -hydroxypropylaminolbenzamidine, [(6-chloro-2-naphthylsulfonyl) -(2-methylthiazol-4-ylmethyl) amino] -2-hydroxypropylamino} benzamidine, diacetate, FAB-544 and II(6-chloro-2-naphthylsulfonyl) -(4-methoxybenzyl) amino] -2-hydroxypropylamino~benzamidine, 71 Z\RAdiacetate, FA-B 553.
99 Similarly, reaction of (5-methyl- oxadiazol-3-yl)phenyl] -2-oxooxazolidin-5-ylmethyl) (4-methoxyphenyl) sulfonamide with iodobutane and subsequent cleavage of the oxazolidinone and the oxadiazole ring similar to Example 3 and 4 gives the compound [(4-methoxyphenylsulfonyl) butylamino] -2-hydroxypropylamino~benzamidine, acetate, FAB 435.
Similarly, reaction of N-{3-[4-(5-methyl-[l,2,4]oxadiazol-3-yl)phenyl] -2-oxooxazolidin-5-ylmethyl) (2-naphthyl) sulfonamide with iodobutane and iodoethane and subsequent cleavage of the oxazolidinone and the oxadiazole ring similar to Example 3 and 4 gives the compounds [(2-naphthylsulfonyl)butylamino] -2-hydroxypropylamino~benzamidine, acetate, FAB 455 and [(2-naphthylsulfonyl)ethylamino] -2-hydroxypropylamino~benzamidine, acetate, FAB 427.
Example 18 Similarly to Example 11, the appropriate cyano derivatives give, by reaction with hydroxylammonium chloride, the compounds below 3- (3-N-hydroxyamidinophenyl) [(4-N-hydroxyamidinophenoxy)methyl]oxazolidin-2-one, m.p. 201-2050, 3- (3-N-hydroxyamidinophenyl) -N-hydroxy- Fc4- amidinophenoxy) methyl] oxazolidin-2-one, 100 3- (4-N-hydroxyamidinophenyl) [(3-N-hydroxyamidinobenzyloxy) methyl] oxazol idin-2 -one, 3- (3-N-hydroxyamidinophenyl) [(3-N-hydroxyamidinobenzyloxy) methyl] oxazolidin-2-one.
Similarly to Example 2, these give, by hydrogenation, the compounds 3- (3-amidinophenyl) -5-[l(4-amidinophenoxy) methyl] oxazolidin-2-one, diacetate, M.P. 150-1660 (decomposition), FAB 354; 3- (3-amidinophenyl) [(3-amidinophenoxy) methyl] oxazolidin-2-one, diacetate, m.p. 312-3180; 3- (4-amidinophenyl) [(3-amidinobenzyloxy) methylloxazolidin-2-one, triacetate, M.P. 189-2050 (decomp.), FAB 368; 3- (3-amidinophenyl) [(3-amidinobenzyloxy) methylloxazolidin-2-one, triacetate, M.P. 204-2220 (decomp.), FAB 368.
Example 19 Similarly to Example 16, reaction of 4-oxiranylethylbenzonitrile and 3-cyanophenol, subsequent reaction with hydroxylammonium chloride and hydrogenation gives the compound 4-[3-hydroxy-4-(3-amidinophenoxy) butyl] benzamidine, diacetate, FAB 327 NH HN NH 2
H
2
N
OH
101 Example Under nitrogen, 10.0 g of 3-(5-methyl-[1,2,4]oxadiazol-3-yl)phenol is added to 50 ml of DMF and 2.6 g of sodium hydride are subsequently added at 00.
5.1 ml of epibromohydrin are added, and the mixture is stirred at room temperature for 24 hours. Customary work-up gives 5-methyl-3-(3-oxiranylmethoxyphenyl)- [1,2,4]-oxadiazol.
8.0 g of the oxiranyl compound are dissolved in 400 ml of methanol and NH 3 gas is introduced for 6 hours. The mixture is stirred for another 16 hours, yielding, after removal of the solvent, l-amino-3-[3-(5-methyl- [1,2,4]-oxadiazol-3-yl)phenoxy]propan-2-ole 500 mg of "AB" and 434 mg of 4-methoxyphenylsulfonyl chloride together with 2.0 g of polymeric DMAP (1.6 mmol of dimethylaminopyridine/g of resin) in 5 ml of pyridine are stirred at room temperature for 24 hours. The resin is filtered off and the filtrate is worked up as usual, giving N-{2-hydroxy-3-[3-(5-methyl- [1,2,4]-oxadiazol-3-yl)phenoxy]propyl}-4-methoxybenzenesulfonamide.
This gives, by hydrogenation similarly to Example 2, the compound 3-[2-hydroxy-3-(4-methoxybenzenesulfonylamino)propoxy]benzamidine, acetate, FAB 380 00
N'
NH OH H Similarly, reaction of "AB" with 4-isopropylphenylsulfonyl chloride, 2-naphthylsulfohyl chloride, 6-chloro-2-naphthylsulfonyl chloride, N 7-methoxy-2-naphthylsulfonyl chloride 102 and subsequent hydrogenation gives the compounds below 3- [2-hydroxy-3- (4-isopropylbenzenesulfonylamino) propoxylbenzamidine, acetate, FAR 392; 3- [2-hydroxy-3- (2-naphthylsulfonylamino)propoxy] benzamidine, acetate, FAB 400; 3- [2-hydroxy-3- (6-chloro-2-naphthylsulfonylamino) propoxyllbenzamidine, acetate, FAR 434; 3- [2-hydroxy-3- (7-methoxy-2-naphthylsulfonylamino)propoxy] benzamidine, acetate, FAB 430; Similarly, reaction of l-amino-3-[4-(5-methyl- oxadiazol-3-yl) phenoxy] propan-2-ole with 4 -methoxyphenylsulfonyl chloride, 4-isopropyiphenylsulfonyl chloride, 2-naphthylsulfonyl chloride, 6-chloro-2 -naphthylsulfonyl chloride, 7-methoxy-2-naphthylsulfonyl chloride and subsequent hydrogenation gives the following compounds 4- [2-hydroxy-3- (4-methoxybenzenesulfonylamino) propoxylbenzamidine, acetate, FAB 380; 4- [2-hydroxy-3- (4-isopropylbenzenesulfonylamino) propoxylbenzamidine, acetate, FAB 392; 4- [2-hydroxy-3- (2-naphthylsulfonylamino)propoxy] benzamidine, acetate, FAB 400; 4-[12-hydroxy-3- (6-chloro-2-naphthylsulfonylamino) propoxylbenzamidine, acetate, FAB 434; 4- [2-hydroxy-3- (7-methoxy-2-naphthylsulfonylamino)propoxyl benzamidine, acetate, FAR 430.
103 Example 21 10.7 ml of sodium methoxide (30% strength in methanol) are added to 30 ml of methanol, 4-(5-methyl-[1,2,4]oxadiazol-3-yl)aniline is added under nitrogen and the mixture is stirred at 450 for 10 minutes. The mixture is subsequently added to a suspension of 480 mg of paraformaldehyde and 20 ml of methanol, and the mixture is stirred at 60 0 C for 2 hours. The mixture is then admixed with 440 mg of sodium borohydride and stirred at 600 for 1 hour. The mixture is subsequently admixed two more times with 1.44 g of paraformaldehyde, 3.1 g of sodium methoxide and 220 mg of sodium borohydride each time.
After [lacuna] hours, the mixture is hydrolyzed using lN NaOH and worked up as usual. This gives, as a crude product, 1.93 g of N-methyl-4-(5-methyl-[1,2,4]oxadiazol-3-yl)aniline.
A solution of 1.35 g of 4-(5-methyl-[1,2,4]-oxadiazol- 3-yl)-N-methylaniline and 1.0 ml of epichlorohydrin in ml of ethanol and 3.5 ml of water is boiled under reflux for 12 hours. Customary work-up gives 0.4 g of N-methyl-N-oxiranylmethyl-4-(5-methyl-[1,2,4]-oxadiazol-3-yl)aniline. A solution of 0.39 g of N-methyl- N-oxiranylmethyl-4-(5-methyl-[1,2,4]-oxadiazol-3-yl)aniline and 30 ml of methylamine (33% strength in ethanol) in 10 ml of ethanol is stirred at 650 for hours. Customary work-up gives 0.44 g of 1-methylamino-3-{methyl-[4-(5-methyl-[1,2,4]-oxadiazol- 3-yl)phenyl]amino}propan-2-ole 100 mg of "BC" and 87 mg of 4-isopropylphenylsulfonyl chloride together with 300 mg of polymeric DMAP (1.6 mmol of dimethylaminopyridine/g of resin) in 5 ml of dichloromethane are stirred at room temperature for 16 hours. The resin is filtered off and the filtrate is worked up as usual. This gives 109 mg of N-(2-hydroxy- 3-{methyl-[4-(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl]amino}propyl)-4-isopropyl-N-methylbenzenesulfonamide.
104 By hydrogenation similarly to Example 2, this gives the compound 4-({2-hydroxy-3-[(4-isopropylbenzenesulfonyl)-Nmethylamino]propyl}-N-methylamino)benzamidine, acetate, FAB 419
NH
N N. OH Similarly, reaction of "BC" with 2-naphthylsulfonyl chloride and subsequent hydrogenation gives the compound 4-({2-hydroxy-3-[(naphth-2-ylsulfonyl)-N-methylamino]propyl}-N-methylamino)benzamidine, diacetate, FAB 427.
The following examples relate to pharmaceutical formulations: Example A: injection vials A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogen phosphate in 3 1 of doubly distilled water is brought to pH 6.5 with 2 N hydrochloric acid and subjected to sterile filtration, and injection vials are filled with the solution, lyophilized under sterile conditions and closed under sterile conditions. Each injection vial contains 5 mg of active compound.
Example B: suppositories A mixture of 20 g of an active compound of the formula I-with-100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed i- ^cy y 105 to cool. Each suppository contains 20 mg of active compound.
Example C: solution A solution is prepared from 1 g of an active compound of the formula I, 9.38 g of NaH 2
PO
4 .2H 2 0, 28.48 g of Na 2
HPO
4 -12H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of doubly distilled water. It is brought to pH 6.8, topped up to 1 1 and sterilized by irradiation.
This solution can be used in the form of eyedrops.
Example D: ointment 500 g of an active compound of the formula I are mixed with 99.5 g of vaseline under aseptic conditions.
Example E: tablets A mixture of 1 kg of active compound of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed into tablets in the customary manner such that each tablet contains 10 mg of active compound.
Example F: coated tablets Tablets are pressed analogously to Example E and are then coated in the customary manner with a coating of sucrose, potato starch, talc, tragacanth gum and dyestuff.
Example G: capsules Hard gelatin capsules are filled with 2 kg of active compound of the formula I in the customary manner such that each capsule contains 20 mg of the active compound.
Example H: ampoules A solution of 1 kg of active compound of the formula I in 60 1 of doubly distilled water is subjected to sterile filtration, and ampoules are filled with the solution, lyophilized under sterile conditions and 106 closed under sterile conditions. Each ampoule contains mg of active compound.
The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement or any form of suggestion that the prior art forms part of the common general knowledge in Australia.
S**
0
S':
«e e*

Claims (3)

1. Compounds of the formula I R 2 in which R1 is -C(=NH)-NH 2 which can also be mono- substituted by -COA, -CO-[C(Rs) 2 ]m-Ar, ICOOA, -OH or -by a conventional amino-protective group, or 0 CH 3 R 2 is H, A, OR 5 N (R 5 2 NO,, CN, Hal, NR 5 COA, NHCOAr, NHOA, NHSO Ar, COOR 5 CON(R 5 2 CONHAr, CORS, COAr, S A or S Ar, R 3 is R' or [C 2 1 .COORs, R' and X together are also thus forming a ring, where R 3 is -C=O and X is N 4e R 4 is A, cycloalkyl, -[C(Rs 2 ]Ar, [C (R) 2 ffHet or 5 -Ar, is H, A or benzyl, X is 0, NR 5 or CH 2 108 Y is 0, NR 5 N[(C (R 5 2 Ij -Ar, N CC R 5 )j,1m-Het, -N N- CC CR 5 2 1 .CON (R 5 2' N CC CR 5 21 .m-CONRsAr or N C C R 5 2 1 mCONAr 2 W is a bond, -So 2 or -CONR 5 A is alkyl having 1-20 C atoms in which one or two CH 2 groups can be replaced by 0 or S atoms or by -CR 5 =CR 5 groups and/or 1-7 H atoms can be replaced by F, Ar is naphthyl or phenyl which is unsubstituted La or mono-, di- or trisubstituted by R 1 A, Ar' OR 5 NCRs) 2 NO 2 CN, Hal, NHCOA, NI{COAr', NHSO 2 A, NHS 2 r',I COOR 5 CON CR 5 2 CONI{Ar', COR 5 COAr'I, S A or S Ar, 0-60:Ar' is naphthyl or phenyl which is unsubstituted 0 0 or mono-, di- or trisubstituted by A, OR 5 NCR 5 2 NO 2 CN, Hal, NHCOA, COOR 5 CONCR 5 2 CORS or SC(0),A, :0 Het is a mono- or bicyclic saturated or unsaturated heterocyclic ring system which contains one, two, three or four identical or different hetero atoms such as nitrogen, oxygen and sulfur and which is unsubstituted or mono- or polysubstituted by Hal, A, Ar' OR 5 COOR 5 CN, N(R 5 NO 2 NHCOA, NHCOAr' and/or carbonyl oxygen, Hal is F, Cl, Br or I, P:\WPDOCS\CAB/sPECI\7483620.do.-I U12101 -109- M iso; 1, 2, 3 or4, n isO 1 or 2,
4.V 4.. a 4
43-. 34.. @4 and salts thereof, with the proviso that the following compounds are excluded: OH N 0 H N' 1 -isop ropyl am in o-3-II4-(5-m ethyIl 1, 2,4]oxad i azo-3-yI)-p h enlOxy-p ro p al 2 -o 1 4 V 4. 4 .4 44 444444 4 .4 4 0 N N I 0 1 -[2-(3,4-dimethoxy-phenyI)-ethylamiflO-3-[4-(5-methyIl [,2,4loxad iazol-3-yI)-phenoxy]- propan-2-oI; and N NN 1 -14-(2-meth oxyp he nyl)-p iperazin- 1 -yII-3-[4-(5-methyl-[1, 2,4]oxad iazol-3-yI)-p hen oxy]- propan-2-oI. P:\WPDOCS\CAB\SPEC\7483620.doc-I 1/12/01 -109a- 2. Compounds according to Claim 1, a) 4- 6-dichloro-4-methoxybenzene- sulfonyl)piperazin--yl] -2-hydroxypropyl- amino }benzamidine; b) 4- {3-[(4-isopropylbenzenesulfonyl)methyl- amino] -2-hydroxypropylamino} benzamidine; c) (1-naphthylbenzenesulfonyl)piperazin- 1-yl] -2-hydroxypropylamino}benzamidine; d) 3-(4-amidinophenyl)-5-[(3-amidinophenoxy)- methyl]oxazolidin-2-one 10 and salts thereof. g* 3. Process for preparing compounds of the formula I according to Claim 1 and salts thereof, S 15 characterized in that 15 a) they are liberated from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent, by i) liberating an amidino group from its oxadiazole derivative by hydrogenolysis, ii) replacing a conventional amino-protective group by treatment with a solvolysing or hydrogenolysing agent with hydrogen or liberating an amino group which is protected by a conventional protective group, 110 or b) that for preparing compounds of the formula I in which R 1 is N*o N-O HN- N= 0 or CH 3 R 3 and X together are thus forming a 5-membered ring, NR, -N N- -N N Y is or N ,N isi W is -SO 2 or -CO-, and R 2 and R 4 are as defined in Claim 1, a compound of the formula II RiR in whichR3 in which 111 R 1 HN-4 N= R 1 is 0 or CH 3 R 3 and X together are thus forming a 5-membered ring, Y NR 5 -N N- N Y is or R 5 R N N and R 2 and R 5 are as defined in Claim 1, is reacted with a compound of the formula III R 4 -W-L III in which W is -S0 2 or -CO-, R 4 is as defined in Claim 1, and L is Cl, Br, I or a free or a reactive functionally derivatized OH group, or c) that for preparing compounds of the formula I in which R 1 is G 112 N.O 0 HN N C 0 or CH 3 R 3 and X together are thus forming a 5-membered ring, Y is O, W is a bond, and R 2 and R 4 are as defined in Claim 1, a compound of the formula II R1 Ii1 X II R 2 ,O R 3 in which R 1 is N 0 N' R HN- N= 0 or CH 3 R 3 and X together are thus forming a ring, Y is O, and R 2 is as defined in Claim 1, is reacted with a compound of the formula IV -R4-W-OH IV in which 113 W is a bond, and R 4 is as defined in Claim 1, or d) that for preparing compounds of the formula I in which HN- N= C R is 0 or CH R 3 and X together are thus forming a ring, -N N-, Y 4 W is a bond, R 4 is -[C(Rs)2]mAr or -[C(R 5 2 ,1 m is 0, and R 2 is as defined in Claim 1, a compound of the formula V 2 v0 R3 ,Het, Cr K r z -y in which 114 HN N=C R 1 is 0 or 3C R 3 and X together are thus forming a 5-membered ring, and L is Cl, Br, I or a free or a reactive functionally derivatized OH group, and R 2 is as defined in Claim 1, is reacted with a compound of the formula VI R 4 -W-Y-H VI in which W is a bond, -N N-, Y is R 4 is [C(R 5 2 mAr or [C(R 5 2 ]mHet and m is 0, or e) that for preparing compounds of the formula I in which \AT 115 HN-{ 0 %.IN.O CH 3 R 1 is or R 3 and X together are thus forming a ring, N R 5 N N ON R 5 o Y is N, N W is -CONH-, and R 2 and R 4 are as defined in Claim 1, a compound of the formula II in which {>N4 0N- or R1 is R 3 and X together are thus forming a ring, (:4 c~jjI' 116 NR 5 -N N- N -N Y is R 5 R or and R 2 and R 5 are as as defined in Claim 1, is reacted with a compound of the formula VII R 4 -N=C=O VII in which R 4 is as defined in Claim 1, or f) that for preparing compounds of the formula I in which N0 {N,0 HN N= R 1 is O or CH 3 R 3 and X together are thus forming a ring, Y is N[C(R 5 2 ]m-COOR 5 W is SO 2 and R 2 and R 4 are as defined in Claim 1, -a compound of the formula II rv IT~i 117 X YH R2 R R 3 in which N N R' HN- N-= R 1 is 0 or CH3 R 3 and X together are thus forming a ring, Y is N[C(R) 2 ]m-COOR 5 and R 2 and R 5 are as defined in Claim 1, is reacted with a compound of the formula VIII R 4 -SO 2 -L VIII in which L is Cl, Br, I or a free or a reactive functionally derivatized OH group, and R 4 is as defined in Claim 1, or g) that for preparing compounds of the formula I in which X is NH and 118 R 3 is H and R 1 R 2 R 4 Y and W are as defined in Claim 1, these compounds are liberated from their oxazolidinone derivatives by treatment with a solvolysing or hydrogenolyzing agent, or h) that for preparing compounds of the formula I in which R 1 is -C(=NH)-NH 2 a cyano group is converted into an amidino group, or I) in a compound of the formula I, one or more radicals Y, R 1 R 2 R 3 and/or R 4 are converted into one or more radicals R 1 R 2 R 3 and/or R 4 by, for example, i) hydrolysing an ester group to give a carboxyl group, ii) reducing a nitro group, iii) acylating an amino group, and/or k) converting a base or acid of the formula I into one of its salts. 119 4. Process for preparing pharmaceutical formulations, characterized in that a compound of the formula I according to Claim 1- and/or one of its physiologically acceptable salts is brought into a suitable dosage form together with at least one solid, liquid or semi-liquid carrier or auxiliary. Pharmaceutical formulation, characterized by a content of at least one compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts together with at least one solid, liquid or semi-liquid carrier or auxiliary. 6. Use of compounds of the formula I according to Claim 1 and their physiologically acceptable salts for combating thromboses, myocardial infarction, arteriosclerosis, inflammations, apoplexy, angina pectoris, restenosis after angioplasty and i 20 20 claudicatio intermittens. 7. Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable I salts for the preparation of a medicament. 9 9 8. Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts for the preparation of a medicament for S: 8 arteriosclerosis inflammations, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens. P:\WPDOCS\CRN\SPECI7483620.spe.doc-30/04 I -120- 9. Method for combating thromboses, myocardial infarction, arteriosclerosis, inflammations, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens which comprises administering to a subject in need of. such treatment at least one compound of the formula I according to claim 1 and/or one of its physiologically acceptable salts together with at least one solid, liquid or semi-liquid carrier or auxiliary. Compounds of the formula I, processes for their preparation or pharmaceutical compositions or methods of treatment involving/containing them, substantially as hereinbefore described with reference to the Examples. DATED this 30th day of April, 2001 e oo 20 MERCK PATENT GMBH 4 By its Patent Attorneys DAVIES COLLISON CAVE *oi* 0 3
AU19647/99A 1997-12-12 1998-11-27 Benzamine derivatives Ceased AU744002B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19755268 1997-12-12
DE19755268A DE19755268A1 (en) 1997-12-12 1997-12-12 Benzamidine derivatives
PCT/EP1998/007673 WO1999031092A1 (en) 1997-12-12 1998-11-27 Benzamine derivatives

Publications (2)

Publication Number Publication Date
AU1964799A AU1964799A (en) 1999-07-05
AU744002B2 true AU744002B2 (en) 2002-02-14

Family

ID=7851688

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19647/99A Ceased AU744002B2 (en) 1997-12-12 1998-11-27 Benzamine derivatives

Country Status (16)

Country Link
EP (1) EP1056743A1 (en)
JP (1) JP2002508370A (en)
KR (1) KR20010032963A (en)
CN (1) CN1281451A (en)
AR (1) AR017844A1 (en)
AU (1) AU744002B2 (en)
BR (1) BR9813477A (en)
CA (1) CA2313651A1 (en)
DE (1) DE19755268A1 (en)
HU (1) HUP0004353A3 (en)
NO (1) NO20002958L (en)
PL (1) PL341008A1 (en)
RU (1) RU2203897C2 (en)
SK (1) SK8572000A3 (en)
WO (1) WO1999031092A1 (en)
ZA (1) ZA9811339B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157456B2 (en) 1999-12-24 2007-01-02 Bayer Healthcare Ag Substituted oxazolidinones and their use in the field of blood coagulation
US7767702B2 (en) 2001-06-20 2010-08-03 Bayer Schering Pharma Aktiengesellschaft Substituted oxazolidinones for combinational therapy
US7932278B2 (en) 2005-09-23 2011-04-26 Bayer Schering Pharma Aktiengesellschaft 2-aminoethoxyacetic acid derivatives and their use
US8106192B2 (en) 2003-01-07 2012-01-31 Bayer Pharma Aktiengesellschaft Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
US8586082B2 (en) 2005-10-04 2013-11-19 Bayer Intellectual Property Gmbh Solid orally administerable pharmaceutical dosage forms with rapid active principle release

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747023B1 (en) * 1998-08-11 2004-06-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
SE9902987D0 (en) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AU2004202422B2 (en) * 1999-12-24 2007-11-22 Bayer Intellectual Property Gmbh Substituted oxazolidinones and their use in the field of blood coagulation
CO5300399A1 (en) 2000-02-25 2003-07-31 Astrazeneca Ab HETEROCICLIOCS CONTAINING NITROGEN, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE10027024A1 (en) * 2000-05-31 2001-12-06 Merck Patent Gmbh Carbamic acid ester
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
US7005439B2 (en) 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
DE10105989A1 (en) * 2001-02-09 2002-08-14 Bayer Ag Substituted oxazolidinones and their use
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
AR035230A1 (en) 2001-03-19 2004-05-05 Astrazeneca Ab BENCIMIDAZOL COMPOUNDS, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION, AND USES OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101038D0 (en) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
SE0103818D0 (en) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
DE10159453A1 (en) * 2001-12-04 2003-06-18 Merck Patent Gmbh Use of 1-phenyl-oxazolidin-2-one compounds as a protease
MXPA04008526A (en) * 2002-03-06 2005-07-13 Toyama Chemical Co Ltd Novel arylamidine derivative or salt thereof.
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
SE0301369D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10322469A1 (en) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclic compounds
WO2005000826A1 (en) * 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
CN101379049B (en) * 2006-01-31 2012-01-04 同和药品株式会社 Novel benzamidine derivative, its preparation method, and pharmaceutical composition containing the derivative
DE102007018662A1 (en) 2007-04-20 2008-10-23 Bayer Healthcare Ag Oxazolidinone for the treatment and prophylaxis of pulmonary hypertension
KR101009594B1 (en) 2007-05-09 2011-01-20 주식회사 레고켐 바이오사이언스 FFA inhibitor having cyclic amidine at P4 position, derivative thereof, preparation method and pharmaceutical composition containing same
WO2008140220A1 (en) * 2007-05-09 2008-11-20 Legochem Bioscience Ltd. Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
DE102007028318A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Oxazolidinone for the treatment and prophylaxis of sepsis
CA2694639A1 (en) * 2007-07-27 2009-02-05 Dong Wha Pharmaceutical Co., Ltd. Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteoporosis comprising the same
EP2138178A1 (en) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
EP2140866A1 (en) 2008-07-04 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
US20120283434A1 (en) * 2010-01-04 2012-11-08 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
US20130109672A1 (en) * 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166132A (en) * 1977-08-18 1979-08-28 Pfizer Inc. Antiviral amine derivatives of glycerol and propanediols
DE4203201A1 (en) * 1992-02-05 1993-08-12 Boehringer Ingelheim Kg NEW AMIDINE DERIVATIVES, THEIR PREPARATION AND USE
DK0623615T3 (en) * 1993-05-01 1999-12-13 Merck Patent Gmbh Adhesion receptor antagonists
DK0710657T3 (en) * 1994-11-02 1999-05-25 Merck Patent Gmbh Adhesion receptor antagonists
DE19504954A1 (en) * 1995-02-15 1996-08-22 Merck Patent Gmbh Adhesion receptor antagonists
DE19516483A1 (en) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhesion receptor antagonists
WO1997023212A1 (en) * 1995-12-21 1997-07-03 The Du Pont Merck Pharmaceutical Company ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS
KR20010021645A (en) * 1997-07-11 2001-03-15 로렌스 티. 마이젠헬더 Thiadiazolyl and Oxadiazolyl Phenyl Oxazolidinone Antibacterial Agents

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157456B2 (en) 1999-12-24 2007-01-02 Bayer Healthcare Ag Substituted oxazolidinones and their use in the field of blood coagulation
US7576111B2 (en) 1999-12-24 2009-08-18 Bayer Schering Pharma Ag Substituted oxazolidinones and their use in the field of blood coagulation
US7585860B2 (en) 1999-12-24 2009-09-08 Bayer Schering Pharma Aktiengesellschaft Substituted oxazolidinones and their use in the field of blood coagulation
US7592339B2 (en) 1999-12-24 2009-09-22 Bayer Schering Pharma Aktiengesellschaft Substituted oxazolidinones and their use in the field of blood coagulation
US8129378B2 (en) 1999-12-24 2012-03-06 Bayer Pharma Aktiengesellschaft Substituted oxazolidinones and their use in the field of blood coagulation
US7767702B2 (en) 2001-06-20 2010-08-03 Bayer Schering Pharma Aktiengesellschaft Substituted oxazolidinones for combinational therapy
US8106192B2 (en) 2003-01-07 2012-01-31 Bayer Pharma Aktiengesellschaft Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
US7932278B2 (en) 2005-09-23 2011-04-26 Bayer Schering Pharma Aktiengesellschaft 2-aminoethoxyacetic acid derivatives and their use
US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
US8586082B2 (en) 2005-10-04 2013-11-19 Bayer Intellectual Property Gmbh Solid orally administerable pharmaceutical dosage forms with rapid active principle release

Also Published As

Publication number Publication date
WO1999031092A1 (en) 1999-06-24
ZA9811339B (en) 1999-07-08
AR017844A1 (en) 2001-10-24
RU2203897C2 (en) 2003-05-10
CN1281451A (en) 2001-01-24
NO20002958D0 (en) 2000-06-09
NO20002958L (en) 2000-08-11
PL341008A1 (en) 2001-03-12
DE19755268A1 (en) 1999-06-17
KR20010032963A (en) 2001-04-25
HUP0004353A2 (en) 2002-03-28
BR9813477A (en) 2000-10-24
JP2002508370A (en) 2002-03-19
SK8572000A3 (en) 2001-07-10
HUP0004353A3 (en) 2002-04-29
AU1964799A (en) 1999-07-05
EP1056743A1 (en) 2000-12-06
CA2313651A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
AU744002B2 (en) Benzamine derivatives
AU736080B2 (en) Benzamidine derivatives
JP2004535362A (en) Phenyl derivative
SK492001A3 (en) Biphenyl derivatives
AU2002363366B2 (en) Derivatives of phenoxy-N- 4-(isothiazolidin-1,1-dioxid-2YL)pheny!-valerian- acid amide and other compounds as inhibitors of the coagulation factor XA in the treatment of thromboembolic diseases and tumors
MXPA04007480A (en) Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase.
AU2004205354B2 (en) Carboxamide derivatives and their use as factor Xa inhibitors
US20030166694A1 (en) Glycinamides
CZ20002126A3 (en) The invention relates to a support body (1) for arranging electrical contacts, which comprises an electrically non-conductive base body in which electrical contacts (3) are arranged. The support body (1) has a modular structure consisting of individual separate elements (2,4) which can be assembled and joined together. Individual elements (2,4) may or may not have contacts (3).
CA2485065A1 (en) Semicarbazide derivatives for combating thromboembolic diseases
US20030199698A1 (en) Carbamic acid esters as inhibitors of factor xa
US20030187037A1 (en) Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia
CZ20001183A3 (en) The benzamidine derivative as a factor XA inhibitor, a process for its preparation, its use and a pharmaceutical composition containing it
MXPA00003094A (en) Benzamidine derivatives as factor xa inhibitors
MXPA04008479A (en) Semicarbazide derivatives and their use as antithrombotics.
SK1992003A3 (en) Urethane derivative, method for its preparation, its use and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired